PF-[ADDRESS_1066738] 2021
PFIZER CONFIDENTIAL
Page 1A PHASE 1, OPEN-LABEL, SINGLE-DOSE STUDY TO INVESTIGATE THE MASS 
BALANCE, METABOLISM AND EXCRETION OF [14C]-PF-07304814 IN 
HEALTHY PARTICIPANTS USING A 14C-MICROTRACER APPROACH
Study Intervention Number: PF-07304814
Study Intervention Name: N/A
US IND Number:EudraCT Number: N/A
ClinicalTrials.gov ID: N/A
Protocol Number: C4611003
Phase: 1
Brief Title: A Phase 1 Study to Investigate the Mass Balance, Metabolism, and 
Excretion of [
14C]-PF-07304814 in Healthy Participants.
This document and accompanying materials contain confidential information belonging to [COMPANY_007]. Except as 
otherwise agreed to in writing, by [CONTACT_22788], you agree to hold this 
information in confidence and not copy or disclose it to others (except where required by [CONTACT_1289]) or 
use it for unauthorized purposes. In the event of any actual or suspected breach of this obligation, [COMPANY_007] 
must be promptly notified.
CCI
PF-[ADDRESS_1066739] 2021
PFIZER CONFIDENTIAL
Page 2Document History
Document Version Date
Amendment #[ADDRESS_1066740] of country  health authorities and IRBs/ECs and any  global protocol administrative 
clarification letter.
Protocol Amendment Summary of Changes Table
Amendment [1] ([ADDRESS_1066741] - 2021)
Overall Rationale for the Amendment: 
Section # and Name [CONTACT_776773] [14C] PF -07304814 
dose from 600 mg (0.5 µCi) to 
500 mg (420 nCi).FDA feedback to reduce the 
dose of PF -07304814.
Section 5.2 Exclusion 
criteriaTotal 14C radioactivity  
measured in plasma exceeding 
11mBq/mL  at Screening.To ensure the background 
radioactivity  in plasma will not 
interfere in accuratel y 
measuring [14C] PF -07304814.

PF-[ADDRESS_1066742] OF FIGURES ...................................................................................................................7
1. PROTOCOL  SUMMARY .....................................................................................................8
1.1. Sy nopsis ....................................................................................................................8
1.2. Schema ....................................................................................................................10
1.3. Schedule of Activities .............................................................................................11
2. INT
RODUCTION ...............................................................................................................15
2.1. Study  Rationale .......................................................................................................15
2.2. Background .............................................................................................................15
2.2.1. Nonclinical Pharmacology ..........................................................................16
2.2.2. Nonclinical Pharmacokinetics and Metabolism
.........................................16
2.2.3. Nonclinical Safet y
......................................................................................16
2.2.4. Clinical Overview .......................................................................................18
[IP_ADDRESS]. Summary  of Clinical Safet y
......................................................18
[IP_ADDRESS]. Summary  of Clinical Pharmacology .........................................19
2.3. Benefit/Risk Assessment
.........................................................................................20
2.3.1. Risk Assessment
.........................................................................................21
2.3.2. Benefit Assessment .....................................................................................22
2.3.3. Overall Benefit/Risk Conclusion ................................................................22
3. OBJECTI
VES AND EN DPOINTS .....................................................................................22
4. STUDY DESIGN .................................................................................................................23
4.1. Overall Desig n
.........................................................................................................23
4.2. Scientific Rationale for Study  Design .....................................................................24
4.2.1. Choice of Contraception/Barrier Requirements ................................ ......... [ADDRESS_1066743] 2021
PFIZER CONFIDENTIAL
Page 45.3. L ifesty le Considerations ..........................................................................................28
5.3.1. Meals and Dietary  Restrictions ...................................................................28
5.3.2. Caffeine, Alcohol, and Tobacco .................................................................29
5.3.3. Activity .......................................................................................................29
5.3.4. Contraception ..............................................................................................30
5.4. Screen Failures ........................................................................................................30
6. STUDY INT
ERVENTION(S) AND CONCOMITANT THERAPY .................................30
6.1. Study  Intervention(s) Administered ........................................................................30
6.1.1. Administration ............................................................................................31
6.2. Prepara tion, Handling, Storage, and Accountability ...............................................31
6.2.1. Preparation and Dispensing ........................................................................32
6.3. Measures to Minimize Bias: Randomization and Blinding .....................................32
6.3.1. Allocation to Study Intervention ................................................................32
6.4. Study  Intervention Compliance ...............................................................................32
6.5. Dose Modification ...................................................................................................33
6.6. Continued Access to Study  Intervention After the End of the Study ......................33
6.7. Treatment of Overdose
............................................................................................33
6.8. Concomitant Therapy ..............................................................................................33
6.8.1. Rescue Medicine .........................................................................................34
7. DI SCONTINUATION O F STUDY INTERVENTION A ND PARTI CIPANT 
DISCONTINUATION/WI THDRAWAL ...........................................................................34
7.1.Discontinuation of Study  Intervention ....................................................................34
7.1.1. ECG Changes ..............................................................................................34
7.2. Par ticipant Discontinuation/Withdrawal From the Study .......................................[ADDRESS_1066744] to Follow up ....................................................................................................35
8. STUDY A SSESSMENTS AND PROCE DURES ................................ ............................... 36
8.1. Efficacy  Assessments ..............................................................................................37
8.2. Safet y Assessments .................................................................................................37
8.2.1. Phy sical Examinations ................................................................................37
8.2.2. Vital Signs ..................................................................................................38
[IP_ADDRESS]. Temperature ..............................................................................[ADDRESS_1066745] 2021
PFIZER CONFIDENTIAL
Page 58.2.3. Electrocardiograms.....................................................................................38
8.2.4. C linical Safety  Laboratory  Assessments ....................................................39
8.2.5. COVID -19 specific assessments .................................................................40
8.3. Adverse Events, Serious Adverse Events, and Other Safet y Reporting .................40
8.3.1. Time Period and Frequency  for Collecting AE and SAE Information .......40
[IP_ADDRESS]. Reporting SAEs to [COMPANY_007] Safety ...............................................41
[IP_ADDRESS]. Recording Nonserious AEs and SAEs on the CRF
...................41
8.3.2. Method of Detecting AEs and SAEs ..........................................................41
8.3.3. Follow -Up of AEs and SAEs ......................................................................41
8.3.4. Regulatory
 Reporting Requirements for SAEs ...........................................42
8.3.5. Environmental Exposure, Exposure During Pregnancy  or 
Breastfeeding, and Occupational Exposure .....................................................42
[IP_ADDRESS]. Exposure During Pregnancy ......................................................42
[IP_ADDRESS]. Exposure During Breastfeeding ................................................44
[IP_ADDRESS]. Occupational Exposure .............................................................45
8.3.6. Cardiovascular and Death Events ...............................................................45
8.3.7. Disease -Related Events and/or Disease -
Related Outcomes Not 
Qualifying as AEs or SAEs ..............................................................................[ADDRESS_1066746]
.............................................................45
[IP_ADDRESS]. Lack of Efficacy ........................................................................45
8.3.9. Medical Device Deficiencies ......................................................................45
8.3.10. Medication Errors .....................................................................................45
8.4. Pharmacokinetics, [14C] Assessment, and Metabolite Profiling ............................. 46
8.4.1. Plasma for Anal ysis....................................................................................47
8.4.2. Urine for Anal ysis.......................................................................................48
8.4.3. Feces Anal ysis............................................................................................48
8.5.Genetic s
...................................................................................................................49
8.5.1. Specified Genetics ......................................................................................49
8.5.2. Retained Research Samples for Genetics
...................................................49
8.6. Biomarkers ..............................................................................................................49
8.6.1. Specified Gene Expression (RNA) Research .............................................[ADDRESS_1066747] 2021
PFIZER CONFIDENTIAL
Page 68.6.3. Specified Metabolomic Research ...............................................................49
8.6.4. Retained Research Samples for Biomarkers ...............................................49
8.7. I mmunogenicit y Assessments .................................................................................50
8.8. Health Economics ...................................................................................................50
9. STATI STICAL CONSI DERATIONS
................................................................................50
9.1. Statistical Hy potheses .............................................................................................50
9.2. A nalysis Sets ...........................................................................................................50
9.3. Statistical Analy ses.................................................................................................51
9.3.1. Pharmacokinetic Analy sis..........................................................................51
[IP_ADDRESS]. Mass Balance .............................................................................51
[IP_ADDRESS]. Der ivation of Pharmacokinetic Parameters (Plasma) ................51
[IP_ADDRESS]. Derivation of Pharmacokinetic Parameters (Urine)
..................52
[IP_ADDRESS]. Metabolic Profiling and Metabolite Identification
....................53
9.3.2. Other Safet y Analyses ................................................................................53
[IP_ADDRESS]. Electrocardiogram Analy ses......................................................53
9.3.3. Other Anal yse(s).........................................................................................54
9.4.Interim Anal yses.....................................................................................................54
9.5. Sample Size Determination ................................ ................................ ..................... 54
10. SUPPORTING DOCUM ENTATION AND OPERATI ONAL 
CONSI DERATIONS ..........................................................................................................55
10.1. Appendix 1: Regulatory , Ethical, and Study  Oversight Considerations ...............55
10.1.1. Regulatory and Ethical Considerations ....................................................55
[IP_ADDRESS]. Reporting of Safety  Issues and Ser ious Breaches of the 
Protocol or I CH GCP .........................................................................55
10.1.2. Financial Disclosure ................................ ................................ ................. 56
10.1.3. I nformed Consent Process ........................................................................56
10.1.4. Data Protection .........................................................................................57
10.1.5. Committees Structure ................................ ................................ ............... 57
[IP_ADDRESS]. Data Monitoring Committee ...................................................[ADDRESS_1066748] 2021
PFIZER CONFIDENTIAL
Page 710.1.9. Study  and Site Start and Closure ..............................................................60
10.1.10. Publication Policy ...................................................................................61
10.1.11. Sponsor’s Qualified Medical Personnel .................................................62
10.2. Appendix 2: Clinical Laboratory  Tests .................................................................63
10.3. Appendix 3: Adverse Events: Definitions and Procedures for Recording, 
Evaluating, Follow -Up, and Reporting .....................................................................65
10.3.1. Definition of AE .......................................................................................65
10.3.2. Definition of an SAE ................................................................................66
10.3.3. Recording/Reporting an d Follow -Up of AEs and/or SAEs During 
the Active Collection Period ............................................................................67
10.3.4. Reporting of SAEs
....................................................................................71
10.4. Appendix 4: Contraceptive and Barrier Guidance ................................................72
10.4.1. Male Participant Reproductive Inclusion Criteria
....................................72
10.4.2. Female Participant Reproductive Inclusion Criteria
.................................72
10.4.3. Woman of Childbearing Potential ............................................................72
10.4.4. Contraception Methods .............................................................................73
10.5. Appendix 5: Genetics ............................................................................................75
10.6. Appendix 6: L iver Safety : Suggested Actions and Follow -Up Assessments .......76
10.7. Appendix 7: ECG Findings of Potential Clinical Concern ...................................78
10.8. Appendix 8: Abbr eviations ...................................................................................[ADDRESS_1066749] 2021
PFIZER CONFIDENTIAL
Page 81.PROTOCOL SUMMARY 
1.1.Synopsis 
Brief Title: A Phase 1 Study to Investigate the Mass Balance , Metabolism , and Excretion of 
[14C]-PF-07304814 in 
Healthy Participants.
Rationale
This open -label, single -dose study  in approximately  5healthy  male and female ( of 
non-childbearing potential only) participants has been designed to characterize mass balance 
and further the understanding of human pharmacokinetics, metabolism , and excretion of 
PF-
07304814 administered at a dose of 500 mg [14C]PF-07304814 containing approximately  
420nCi [14C] PF -[ADDRESS_1066750] sample 
size used for mass -balance/ADME studies which include assessment of metabolic profiling 
and is not based on empi[INVESTIGATOR_776746].
Objectives and Endpoints
Objectives Endpo ints
Prim ary: Prim ary: 
To confirm mass balance and 
characterize the routes of elimination of 
[14C]-PF-07304814 and drug related 
materials following 420 nCi/500 mg 
dose of [14C] PF -07304814Amount of [14C]recovered in urine and feces, as a 
percent of the total dose [14C]administered
Toevaluate the PK of PF-07304814 and 
PF-00835231 in plasma andcharacterize 
the PK of total [14C]in plasmaPlasma PK parameters , including AUC last, AUC inf, Cmax, 
Tmax, C24, CL, V ss, and t½
Total [14C] in plasma and PK of PF -07304814 and 
PF-00835231 in plasma
Secondary Objective: Secondary: 
To identify metabolites of PF -07304814
in plasma, urine and feces, if possible Identification and determination of relative abundance of 
the metabolites of PF -07304814 in plasma, urine, and 
feces
To evaluate the safety and tolerability of 
a single, 24 -hour constant -rate, 
continuous infusion of 500mg 
PF-07304814 containing 
420nCi[14C]-PF-07304814 in healthy 
participantsAssessment of TEAE s, clinical laboratory abnormalities, 
vital signs, physical exam, and [ADDRESS_1066751] 2021
PFIZER CONFIDENTIAL
Page 9Overall Design
Brief Summary
This is a Phase 1, open- label, single -dose, single -center study  to characterize mass balance 
and evaluate the pharmacokineti cs, metabolism, and route and extent of elimination of 
[14C]-PF-07304814 in healthy  male and female ( of non -childbearing potential) participants. 
The study will enroll approximately  5healthy  participants. Each participant will receive a 
single, 24
-hour constant -rate, continuous IV infusion of 500 mg PF -07304814 containing 
approximately  420 nCi [14C] PF - 07304814 .
Health y participants will be screened to determine eligibility  within 42days prior to dosing 
to confirm that they  meet the inclusion andnot the exclusion criteria specified in Section 5.1
andSection 5.2, respectively .Medical history  and results of phy sical examination, vital 
signs, 12 -lead ECGs, and clinical laboratory  evaluations will determine eligibility . 
Participants will admitted to the clinical research unit (CRU) on Day  -1 and remain in the 
CRU until the end of the study through Day  10.
On Day  1, each participant will receive a single, 24 -
hour, constant rate, continuous I V 
infusion of 500 mg PF-07304814 containing approximately  420 nCi [14C] PF-07304814. 
Serial blood samples will be collected at specified times (see S
oAfor details) up to [ADDRESS_1066752] before dosing 
(“blank”) and in 24-hour intervals until the end of the study . Feces will be collected from 
Day -1 (“blank”), and at the time of passing while the participant is confined in the clinic. 
Daily  sample collections will continue through the m orning of discharge. 
Participants will be 
confined from at least [ADDRESS_1066753] the morning of Day 10
(216 hours) post infusion start. 
Complete physical examinations, BP, pulse rate, oral temperature, ECGs, and safet y 
laboratory  tests will be conducted, and AEs and concomitant medications will be monitored 
throughout the stud y to assess safet y. Before the participant is released, a complete physical 
examination will be conducted along with safety  labs, ECG, BP, heart rate and oral 
temperature. 
A safet y follow- up call will be made to participants 28 to 35 day s from administration of the 
dose of study  intervention .
Number of Participants
Approximately  5participants will be enrolled toreceive study  intervention .
Note: "Enrolled" means a participant's, or his legally  authorized representative’s, agreement 
to participate in a clinical study  following completion of the informed consent proce ssand 
screening . A participant will be considered enrolled if the informed consent is not withdrawn 
prior to participating in any  study  activity  after screening .Potential participants who are 

PF-[ADDRESS_1066754] udy, but do not participate in the 
study , are not considered enrolled, unless otherwise specified b y the protocol.
Intervention Groups and Duration
Each enrolled participant will receive a single, 24 -hour constant -rate continuous I V infusion 
of 500mg PF -07304814 containing approximately  420 nCi [14C] PF-[ADDRESS_1066755] Follow -up 
phone call, is approximately up to 11 weeks.
Data Monitoring Committee or Other Independent Oversig ht Committee : No
Statistical Methods
There is no formal research hy pothesis to be statistically  tested for this study . The purpose of 
this study  is to assess the PK, metabolism, routes and extent of elimination, as well as safet y 
and tolerability  of a single, 24- hour constant -rate, continuous IV infusion of 500mg 
PF-07304814 containing approximately  420 nCi [14C] PF - [ADDRESS_1066756] 2021
PFIZER CONFIDENTIAL
Page 111.3. S chedule of Activ ities
The SoA table provides an overview of the protocol visits and procedures. Refer to the STUDY ASSESSMENTS AND 
PROCEDURES section of the protocol for detailed information on each procedure and assessment required for compliance with the 
protocol. 
The investigator may  sche dule visits (unplanned vis its) in addition to those listed i n the SoA table , in order to conduct evaluations or 
assessments required to protect the well -being of the participant .
Visit Identifiera
Abbreviations used in 
this table may be found 
in Appendix 8.Screening Study Period Follow -Up Early 
Termination/
Discontinuation
Days Relative to Day [ADDRESS_1066757]
Hours After Start of 
Infusionpredose 00.5 1 2 612 24 25 27 32 48 72 96 120 144 216
Informed consent X
CRU confinementbX                 X
Inclusion/exclusion 
criteriaX X
Medical/medication 
history (update)cX X
Physical examdX X X X
Safety laboratoryeX X X X X X X
DemographyfX
Contraception checkgX X X
Urine drug testinghX X
FSH (females only) X
12-Lead ECGiX X X X X X X
Blood pressure , pulse 
rate, and temperaturejX X X X X X X X
HIV, HBsAg, HCVAb X
COVID -[ADDRESS_1066758] 2021
PFIZER CONFIDENTIAL
Page 12Visit Identifiera
Abbreviations used in 
this t able may be found 
in Appendix 8.Screening Study Period Follow -Up Early 
Termination/
Discontinuation
Days Relative to Day [ADDRESS_1066759]
Hours After Start of 
Infusionpredose 00.5 1 2 612 24 25 27 32 48 72 96 120 144 216
PF-07304814
administrationnX     X
Blood sample for PK 
Total [14C]oX X X X X X X X X X X X X X X X X X
Blood samp le for 
unlabeled PF-07304814
& PF-00835231 PKoX X X X X X X X X X X X X X X X
Blood sample for 
metabolite profilingpX X X X X X X
Fecal collectionqX X 0-24 h our 24-48 hour 48-72 
hour72-96 
hour96-120 
hour120-144, 
144-168, 
168-192, and 
192-216 h our
Urine collectionrX 0-24 h our 24-48 hour 48-72 
hour72-96 
hour96-120 
hour120-144, 
144-168, 
168-192, and 
192-216 h our
Retained Research 
Sample for Genetics 
(Prep D1)sX
CRU discharge X
Serious and nonserious 
AEmonitoringX                   X X
a.Day relative to start of study intervention (Day 1).
b.Participants will be admitted to the clinic on Day -1. Participants will be discharged on Day 10follow ing the final assessments. 
c.Medical history will include a history of prior illegal drug, alcohol, and tobacco use, as w ell as bloo d donation within prior 60 days. Medical history will 
be recorded at Screening and updated on Day -1. 
d.A complete physical exam (PE), w ithout genitourinary evaluation will be performed by [CONTACT_776766] -1 (height and weight must be obtained at Screening to obtain BM I for eligibility criteria) and on Day [ADDRESS_1066760] 2021
PFIZER CONFIDENTIAL
Page 13Visit Identifiera
Abbreviations used in 
this t able may be found 
in Appendix 8.Screening Study Period Follow -Up Early 
Termination/
Discontinuation
Days Relative to Day [ADDRESS_1066761]. Additional safety laboratory assessments may be performed at a ny time at the discretion of the 
investigator. 
f.Dem ographics will include participant race, ethnicity, age, and gender during the screening visit. 
g.Participants will be counselled regarding contraception requirements on Screening ,Day -1, and Follow -up.
h.Urine drug and cotinine (mandatory) and alcohol urine test (at discretion of investigator) will be performed at Screening and o n Day -1. These tests may be 
performed at any other time at the discretion of the investigator. 
i.All ECG assessments will be made a fter at least a [ADDRESS_1066762] 
will be performed after approximately 4 days (ie, upon completion of 4 × 24 hours in house), or if they develop COVID -[ADDRESS_1066763] daily during residence. On days in which vitals are being collected, temperature w ill only need to be taken once and documented. 
n.PF-07304814 will be administered as a constant-rate, continuous IV infusi on, over 24 hours.
o.One ( approximately 4mL) blood sample for unlabeled PF-07304814 and PF-00835231 PK and one (approximately 4mL) blood sample for PK of total 
[14C] analysis will be taken at the following timepoints: pre -dose (a single approximately 20 mL sample will be collected), and at 0.5, 1, 2, 6, 12, 24 (to be 
taken immediately prior to end of infusion), 25, 27, 32, 48, 72, 96, 120, 144, and [ADDRESS_1066764] th e start of infusion . One (approximately 4 mL) blood 
sample will be collected at screening to measure the total radioactivity.
p.One ( approximately 10mL) blood sample will be collected at the times specified in the table for metabolite profiling.
q.Each bow el movement starting from the time of dosing must be collected at the time of passing while the subject is confined in the clini c. Date, and time 
must be recorded. A fecal sample from Day -1 to Day 1 prior to dosing (feces “blank”), if possible. If an individ ual subject has not experienced a bowel 
movement within 36 h ours of their previous bow el movements, fluid intake should be increased and administration of a mild laxative (eg, prune juice or a 
mild stool softener) should be implemented, with the goal to fa cilitate at least 1daily bow el movement. The use of the laxative should be recorded.
r.Urine samples will be collected daily through the morning of discharge. Each urine void must be collected. Each participant w ill empty his/her bladder 
prior to dosing, an d a 10 mL aliquot from this urine (urine “blank”) will be retained. Postdose urine samples will be collected at voiding and l abeled for the 
appropriate [ADDRESS_1066765] 2021
PFIZER CONFIDENTIAL
Page 14Visit Identifiera
Abbreviations used in 
this t able may be found 
in Appendix 8.Screening Study Period Follow -Up Early 
Termination/
Discontinuation
Days Relative to Day [ADDRESS_1066766]
Hours After Start of 
Infusionpredose 00.5 1 2 612 24 25 27 32 48 72 96 120 144 216
s.Prep D1 Retained Research Samples for Genetics: If not collected on the designated collection day, collect at the next available time point when 
biospecimens are being collected in conjunction with a participant visit.
t.A safety follow -up call will be made to participants [ADDRESS_1066767] 2021
PFIZER CONFIDENTIAL
Page 152.INTRODUCTION
PF-07304814 is a phosphate prodrug of PF -00835231, a potent and selective inhi bitor of the 
SARS -CoV -2 3CL  protease, that is being developed as a constant -rate continuous I V 
infusion for the treatment of patients hospi[INVESTIGATOR_776747] D-19. Additional information 
for this compound may  be found in the investigator’s brochure (IB).
2.1.Study Rationale 
The purpose of this study is to characterize mass balance and further the understanding of 
PK, metabolism , and elimination of PF-07304814 and PF- 00835231 (active moiety ). The 
knowledge of routes of elimination and metabolites is useful for evaluating the likelihood of 
effects of renal or hepatic impairment on the disposition of PF -07304814 and PF -00835231 
(active moiet y). The biotransformation anal ysis will be used to identify  metabolites of 
PF-07304814 , if possible . The knowledge gained in this study  may  guide study  designs to 
address potential drug- drug interactions (DDI) and special population studies. 
2.2.Background 
Disease Overview
In December 2019, COVID -[ADDRESS_1066768] occurred.2
COVID -19 manifests as a wide range of illness, from asy mptomatic infection to severe 
pneumonia, ARDS and death. While the majority  of cases (approximately  80%) are 
asymptomatic or mild3, patients who are hospi[INVESTIGATOR_21391] -[ADDRESS_1066769] significant 
morbidity  and mortality4,5, and are at increased risk of developi[INVESTIGATOR_776748]
-inflammatory  cytokines, ARDS, acute 
cardiac injury , thromboembolic events, hy percoagulability , and/or kidney  injury .6-[ADDRESS_1066770] become available in multiple countries to prevent 
infection with SARS -CoV -2. However, a side from sy mptomatic and/or supportive treatments 
there are 
still fewanti-viral drugs that are available to treat COVID-19. A number of 
different classes of drugs are being evaluated or newly  developed to treat hospi[INVESTIGATOR_139096] -19. 
While numerous studies investigating various classes of drugs are ongoing and data are
rapi[INVESTIGATOR_776749], a limited number of therapeutic agents have demonstrated clinical benefit
in large -scale, randomized, controlled clinical trials. Thus, there remains an urg ent need for 
additional safe and more effective therapeutic interventions that improve time to clinical 
recovery  and that prevent the progression of infection to more severe disease and death. As 
the first protease inhibitor engineered to specifically  target the coronavirus 3CL  protease,

PF-[ADDRESS_1066771] ion.
Rationale for Development of PF -07304814
PF-07304814 is a phosphate ester prodrug of PF -00835231, a new potent and selective
inhibitor of the SARS -CoV -2 3CL  protease under development for the treatment of patients
hospi[INVESTIGATOR_21391] -19.
The SARS 3CL  protease is a virally  encoded enzyme that is critical to the SARS -CoV -2 life
cycle, analogous to other obligatory  virally  encoded proteases (eg, HIV protease, HCV
protease).11Mutagenesis experiments with other coronaviruses and pi[INVESTIGATOR_776750] -CoV -2 (pi[INVESTIGATOR_295347]- like supercluster) have demonstrated that the activity
of the 3CL  protein (or t he corresponding pi[INVESTIGATOR_295348] 3C enzy me) is essential for viral
replication. No close human analogs of the SARS 3CL  enzy me are known, suggesting that
appropriate SARS 3CL  inhibitors may  function as selective anti -SARS therapeutic agents.
PF-[ADDRESS_1066772] a panel of human proteases, as well as HIV and HCV proteases.
2.2.1. Nonclinical Pharmacology
Details of the nonclinical pharmacology  of PF-07304814 can be found in the current 
Investigator Brochure (IB).
2.2.2. Nonclinical Pharmacokinetics and Metabolism
Preliminary  human in vitro metabolism data indicate PF -[ADDRESS_1066773]  for
PF-00835231 is predicte d to be via CYP3A4 metabolism (fm 0.76) with minor contributions
from additional CYPs (fm 0.12) and via renal clearance (fm 0.12).
Further details may  be found in the IB.
2.2.3. Nonclinical Safety
The toxicity  profile of PF -07304814 or PF-00835231 was assessed in GLP continuous I V
infusion studies for up to 14 day s in rats and cy nomolgus monkey s. In both studies, animals
were administered control or PF- 07304814 at doses of 70, 360, and 1000 mg/kg/day  as a
continuous I V infusion.

PF-[ADDRESS_1066774] article related effects in rats
up to 1000 mg/kg for up to 14- days. There were no PF -[ADDRESS_1066775] animals, including controls,
had signs of low -grade inflammation as suggested by  [CONTACT_776767], and thrombi at
infusion site or in lu
ngs, which are likel y attributable to infusion/catheter -related
procedures.12There were no PF-07304814 -related effects on respi[INVESTIGATOR_776751].
The infusion studies were associated with increased inflammation also noted in the 
concurrent control groups in both rat and monkey
 studies. However, exacerbation of
infusion/procedure -related inflammatory  effects by  [INVESTIGATOR_16335]-[ADDRESS_1066776] dose tested (1000 mg/kg/day ) was considered above
MTD. These effects included changes in peripheral blood WBC counts, coagulation
parameters, inflammatory cell infiltrates in various tissues, and thrombo- emboli at the
infusion site and/or in different tissues. These effects are monitorable through peripheral
blood chemistry , coagulation, and hematology evaluations. Findings in the recovery  phase
were consistent with resolution of dosing phase infla mmation related to the infusion
procedure. The NOAEL in the 14- day GLP rat study  was 1000 mg/kg/day , representing 
16×and 14 ×the predicted human unbound C maxand AUC 24, respectively, for the active 
moiety PF-[ADDRESS_1066777] tolerated dose (360 mg/kg/day ) in the 
14-dayGLP monkey  study  were 16 ×and 13 ×the predicted human unbound C maxand 
AUC 24,respectively, for the active moiet y PF-[ADDRESS_1066778] target organs of toxicity  were identified, the NOAEL was 
identified as 70 mg/kg/day  based on severity  of procedure -related exacerbation of 
inflammation. Moderate mixed cell inflammation within t he heart and lung observed in a 
single female at 360 mg/kg/day  with evidence of tissue injury  was considered adverse. This 
female had the highest exposure to the active moiety  PF-00835231 on Day  14 compared with 
others in the group. The NOAEL dose of 70 mg /kg/day  represent 2.8× and 2.2 ×the predicted 
human unbound C maxand AUC 24, respectively, for the active moiet y PF-00835231.
A battery  of safet y pharmacology endpoints (neurological, respi[INVESTIGATOR_696] , and cardiovascular)
incorporated into the 24 -hour or 14 -day toxicity  studies indicated the lack of safet y
pharmacology  concerns related to the administration of PF -07304814. PF -07304814, and
PF-
00835231 were negative in the in vitro bacterial reverse mutation assay and did not
induce micronuclei formation in vitro or in vivo. Both compounds had minimal potential for
secondary  (off-target) pharmacology  at clinically  relevant exposures and were compatible
with human blood.
The nonclinical safety profile of PF -[ADDRESS_1066779] 2021
PFIZER CONFIDENTIAL
Page 182.2.4. Clinical Overview
PF-07304814 has been evaluated in a Phase 1 study  (C4611007) evaluating the safet y, 
tolerability  and PK of PF -07304814 as a 24-hou r infusion in healthy  participant s 
(LPLV:17December 2020). Preliminary  data are also available from a Phase 1b study  
(C4611001) in COVID -19 patients evaluating the safet y, tolerabilit y and pharmacokinetics 
(PK) of escalating doses of PF -07304814 given as a 24-hour intravenous (IV) infusion in 
Part1 and as a 120 -hour infusion in Part 2.
Further details may  be found in the IB.
[IP_ADDRESS]. Summary of Clinical Safety
Study  C4611007 consisted of 2 interleaving cohorts with a total of 15 healthy  adult 
participants evaluable for safet y data. Single doses of PF -07304814 ranging from 50 to 
700mg were evaluated. At the 50 mg and 500 mg dose level 6 participants were exposed to 
study  drug, at the 150 mg and 700 mg dose level 5 participants were exposed to study  drug; 
2participants were exposed to placebo at each dose level.
Following a single 50, 150, 500, or 700 mg dose of PF
-07304814 administered as a 24-hour 
infusion in healthy  participants, a total of 20 all -causality  treatment emergent adverse events 
(TEAEs) were reported by  12 participants across the di fferent treatment groups. There were 
no deaths, serious adverse events (SAEs), severe AEs or discontinuations due to AEs during 
this study . There were no individual laboratory  abnormalities assessed as clinically  
significant b y the Investigator.
In the ong
oing stud y in hospi[INVESTIGATOR_776752] D-19 patients (C4611001), as of the data cut -off 
snapshot (26 March2021), [ADDRESS_1066780] been enrolled in Part 1 and 8 participants in 
Part2. In Part 1, 4 participants were dosed at 250 mg dose (PF -07304814 or placebo) and 
4 participants were dosed at 500 mg dose (PF- 07304814 or placebo) in a blinded manner. In 
Part2, 6 participants were dosed with PF -07304814 at 250 mg/day  for 5 day s (~120 -hour
infusion) and 2 participants received placebo for the same duration, in a blinded manner. 
Seven TEAEs were reported by  3 participants in Part 1 (24 hour infusion ), 250 mg does 
cohort . Four AEs were considered mild; 1 AE of coagulopathy  was considered moderate, and 
2 AEs respi[INVESTIGATOR_776753], were severe. AE of 
worsening of COVID pneumonia was considered serious (SAE). Except for 1 AE of 
hematuria experienced by  1 participant, all other AEs were not related to study  treatment. In 
Part1 (24 -
hour infusion), 500 mg dose cohort, 12 TEAEs were reported by 3 participants. 
Ten AEs were mild and 2 were severe and serious (SAEs). None of the AEs were considered 
treatment -
related. Two SAEs of deep venous thrombosis (DVT) of the subclavian vein at the 
site of the midline placement occurred in 2 participants, 1 of whom was dosed with 500 mg 
PF-07304814 and the other participant received placebo (sentinel group within the cohort).

PF-[ADDRESS_1066781] 2021
PFIZER CONFIDENTIAL
Page 19In Part 2 (120-hour infusion) 250 mg/day  cohort of the ongoing study  C4611001, complete 
data were available from first 6 participants enrolled in the cohort. Of these 6 participants, a 
total of 2 TEAEs were reported by 1 participant. Both of the AEs were considered to be 
unrelated to stud y treatment. Additional, preliminary SAE data were available after the 
snapshot date (26 March 2021) from last 2 participants enrolled in the cohort. Overall, 
3SAEs were reported b y these 2 participants. One participant reported acute respi[INVESTIGATOR_776754]- associated pneumonia and the other participant 
experienced worsening of dy spnea. None of these SAEs were considered related to study  
treatment.
The preliminary  and cumulative data from studies C4611007 and C4611001 show a safety  
profile that supports continued investigation of PF-07304814 in clinical studies. More 
detailed information about the known and expected benefits and risks and reasonabl y 
expected AEs of PF -07304814 can be found in the IB. 
[IP_ADDRESS]. Summary of Clinical Pharmacology
Following single ascending 24 -hour IV infusions of PF -07304814 to healthy  participants at
doses of 50 mg, 150 mg, 500 mg, and 700 mg, near maximum plasma concentrations for 
PF-00835231 (the active moiety ) were generally  first observed ~6h post start of the infusion 
and sustained until the end of the infusion. PF -00835231 plasma concentrations declined 
rapi[INVESTIGATOR_776755] t½ values of 1.97 hours and 1.74 hours for the 
500mg and 700 mg doses, respectivel y where these could be calculated and reported. 
PF-00835231 sy stemic exposure based on geometric mean AUC lastand C maxvalues appeared 
to increase in a dose proportional manner across all doses. Geometric mean C ssvalues also 
increased in a dose proportional manner across all doses. Based on the geometric mean Ae%, 
approximately  9%- 11% of the PF -07304814 dose was recovered in urine as the active moiet y 
PF-00835231 across all doses.
Following single ascending 24 -hour IV infusions of PF -07304814 (a phosphate prodrug) at 
doses of [ADDRESS_1066782] observed ~[ADDRESS_1066783] 
start of the infusion were below the limit of detection. PF -07304814 sy stemic e xposure based 
on geometric mean AUC lastvalues appeared to increase in a dose proportional manner 
between the 150 mg and 700 mg doses, however this relationship could not be fully  assessed 
for the 50 mg dose due to the high variability  and levels being clo se to or near the lower limit 
of detection (40 ng/mL). Geometric mean C maxvalues and C ssappeared to increase in a dose 
proportional manner across the dose range studied.
Further details may  be found in the IB.

PF-[ADDRESS_1066784] 2021
PFIZER CONFIDENTIAL
Page 202.3.Benefit/Risk Assessment
PF-07304814 will not provide an y clinical benefit to healthy participants. This study  is 
designed primaril y to further the understanding of human PK, 
metabolism , and elimination of 
PF-07304814 and PF-00835231 (active moiet y).
Since the administered radioactivity  is very  low ( eg, <1000 nCi), participants will be exposed 
to extremely  low amounts of radiation and therefore supporting data such as a dosimetry  
study  in animals are not required.
More detailed information about the known and expected benefits and risks and reasonabl y
expected adverse events of PF-07304814 may  be found in the investigator’s brochure , which 
is the SRSD for this study
.

PF-[ADDRESS_1066785] 2021
PFIZER CONFIDENTIAL
Page 212.3.1. Risk Assessment
Potential Risk of Clinical Significance Summary of Data/Rationale for Risk Mitigation Strategy
Study Intervention(s) PF-07304814
Potential risks associated with PF-07304814 include
inflammatory effects, noted by [CONTACT_776768], coagulation parameters, inflammatory 
cell infiltrates in various tissues, and thrombo -
emboli at the infusion site and/or in different tissues.The potential risks are based on the nonclinical 
study findings. Thrombosis and increased
inflammation were observed follow ing prolonged 
exposure of PF-07304814 noted in the 14 -day
NHP toxicology study.
Informatio n is available in the SRSD for 
PF-07304814 .As this is an investigational agent, there is some 
risk that is mitigated by [CONTACT_486823], 
vital signs, ECGs and laboratory assessments.
Participants with a history of throm botic events 
will be exclud ed.
Study Procedures
Potential for irritation at the intravenous
catheterization site which is required for
administration of the study intervention .Intravenous catheterization may cause pain at the 
site of insertion, bruising, hematoma formation,
bleeding, extravasation, and possibly infection at 
the catheter site, or bloodstream infection.Aseptic technique may mitigate the risk of 
infection. Other adverse effects can be managed
via local care (eg, applying pressure to the site to 
stop bleeding) a nd/or analgesia.
Potential for increased risk of intravenous infusion 
site reaction .There may be potential risk for infusion site 
reaction due to the low pH of study intervention
and/or the need for continuous intravenous 
infusion. These risks are described in the SRSD for
PF-07304814.Monitoring of reactions will be performed 
through targeted PE and collection of AEs, which 
willbe reviewed on an ongoing basis.
If an individual participant is unable to tolerate 
the continuous infusion, based on AEs , treatment
may need to be discontinued.
Other (Not Applicable)

PF-[ADDRESS_1066786] 2021
PFIZER CONFIDENTIAL
Page 222.3.2. Benefit Assessment
PF-07304814 will not provide an y clinical benefit to healthy participants. The purpose of the 
study  is to characterize mass balance and further the understanding of human metabolism of 
[14C] PF - 07304814. 
2.3.3. Overall Benefit /Risk Conclusion
PF-
07304814 will not provide an y clinical benefit to healthy participants in this study .
Taking into account the measures taken to minimize risk to participants of thi s study , the 
potential risks identified in association with administration of PF-07304814 are justified by  
[CONTACT_768746], in terms of contribution to the process of developi[INVESTIGATOR_776756] y in 
an area of unmet medical need.
3.OBJECTIVES AND ENDPO INTS
Objectives Endpoints
Prim ary: Prim ary: 
To confirm mass balance and 
characterize the routes of elimination of 
[14C]-PF-07304814 and drug related 
materials following 420 nCi /500mg 
dose of [14C] PF -07304814Amount of [14C]recovered in urine and feces, as a 
percent of the total [14C]dose administered
Toevaluate the PK of PF-07304814 and 
PF-00835231 in plasma andcharacterize 
the PK of total [14C]in plasmaPlasma PK parameters , including AUC last, AUC inf, Cmax, 
Tmax, C24, CL, V ss,and t½
Total [14C] in plasma and PK of PF -07304814 and 
PF-00835231 in plasma
Secondary Objective: Secondary: 
To identify metabolites of PF -07304814
in plasma, urine and feces, if possible Identification and determination of relative abundance of 
the metabolites of PF -07304814 in plasma, urine, and 
feces
To evaluate the safety and tolerability of 
a single, 24 -hour constant -rate, 
continuous infusion of 500 m g 
PF-07304814 containing 
420nCi[14C] -PF-07304814 in healthy 
participantsAssessment of TEAE s, clinical laboratory abnormalities, 
vital signs, physical exam, and [ADDRESS_1066787] 2021
PFIZER CONFIDENTIAL
Page 234.STUDY DESIGN
4.1.Overall Design
This is a Phase 1, open -label, single -dose, single -center study  to characterize mass balance 
and further the understanding of human PK, met abolism, and excretion of 
[14C]PF-07304814. The study  will be conducted in approximately  5healthy  participants. 
Each participant will receive a single, 24 -hour constant -rate, continuous IV infusion of 
500mg PF -07304814 containing approximately  420 nCi [14C] PF - 07304814.
Approximately  5participants will be enrolled. Each participant will be screened to determine 
eligibility within 42days prior to dosing to confirm that they  meet the inclusion and not the 
exclusion criteria specified in Section 5.1 andSection 5.2, respectivel y.Medical history  and 
results of phy sical examination, phy sical measurements, vital signs, 12 -lead ECGs, and 
clinical laboratory  evaluations will determine eligibility . Participan tswill be admitted to the 
CRU on Day  
-1 and remain in the CRU through Day  10. Participants will be discharged on 
Day 10 following the final assessments. 
Participants who withdraw will not be replaced
unless the number of completed participants falls below 4. Refer to Figure 1 for details. 
On Day  1, each participant will receive a single, 24 -hour constant -rate, continuous I V 
infusion of 500 mg PF-07304814 containing approximately  420 nCi [14C] PF- 07304814. 
Serial blood samples will be collected at specified times (see SoA for details) up to 
216hours 
post the start of the infusion. Total urine collections will be made just before dosing 
(“blank”) and at 24-hou r intervals until the end of the study . Feces will be collected from 
Day -1 (“blank”), and at the time of passing while the participant is confined in the clinic. 
Daily  sample collections will continue through the morning of discharge. Participants will be 
confined from at least [ADDRESS_1066788] the morning of Day 10
(216 hours) 
post infusion start. 
Comple tephysical examinations, BP, pulse rate, oral temperature, ECGs, and safet y 
laboratory  tests will be conducted, and AEs and concomitant medications will be monitored 
throughout the stud y to assess safet y. Before the participant is released, a complete physical 
examination will be conducted along with safety  labs, ECG, BP, heart rate and oral 
temperature. 
A safet y follow- up call will be made to participants approximately  [ADDRESS_1066789] 2021
PFIZER CONFIDENTIAL
Page 244.2.Scientific Rationale for Study Design
This study  is a Phase 1 open- label, single -dose study  in healthy  males and females of 
non-childbea ring potential , designed to characterize mass balance and investigate the PK, 
metabolism , and excretion of [14C] PF - 07304814 ,characterize plasma, fecal, and urinary  
[14C] and identify  anymetabolites, if possible . The knowledge of themetabolism and route s
of elimination of PF-07304814 ,PF-00835231 (active moiety ), and associated metabolites is 
useful for evaluating the likelihood of effects of renal or hepatic impairment on the overall 
disposition . 
The sample size of approximately  5was selected to ensur e at least 4 fully  evaluable 
participants with completed collections of plasma, urine, and fecal samples. 
Knowledge gained in this study  will help guide study  designs to address potential drug 
interactions and special population studies.  
4.2.1. Choice of Contr aception/Barrier Requirements
Human reproductive safety  data are not available for PF-
07304814, but there is no suspi[INVESTIGATOR_776757]. Therefore, 
the use of a highl y effective method of contrac eption is required (seeSection 10.4).
4.2.2. Collection of Retained Research Samples
Retained Research Samples will be collected and stored for further anal yses which may , for 
example, provide greater understanding of the study  intervention.
4.3.Justification for Dose
The total drug dose of [ADDRESS_1066790] dose evaluated in healthy  
participants (700 mgIV administered over 24 hours) , which was safe and well tolerated. A 
dose of [ADDRESS_1066791] completed the study  if he/she has completed all 
periods of 
the study ,including the last visit or the last scheduled procedure shown in the SoA.

PF-[ADDRESS_1066792] y:
Age and Sex :
1.Male and female p articipant smust be 18 to 55years of age ,inclusive, at the time of 
signing the ICD.
Women must be of non- childbearing potential: must meet the criteria for 
WNOCBP outlined in Section 10.4.3.
Refer to Appendix 4forreproductive criteria for male (Section 10.4.1) and female
(Section 10.4.2) participant s.
Type of Participant and Disease Characteristics:
2.
Participants who are overtly  health y as determined by [CONTACT_776769] , phy sical examination, labora tory tests, and ECGs.
3.Participants who are willing and able to compl y with all scheduled visits, treatment 
plan, laboratory  tests, lifesty le considerations, and other study  procedures.
Weight:
4.BMI of 18to 32kg/m2; and a total body  weight >50 kg (110 lb).
Informed Consent:
5.
Capable of giving signed informed consent as described in Appendix [ADDRESS_1066793] 2021
PFIZER CONFIDENTIAL
Page 265.2. Exclusion Criteria
Participa nts are excluded from the study  if any  of the following criteria apply :
Medical Conditions:
1.Evidence or history  of clinically  significant hematological, renal, endocrine, 
pulmonary , gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic al, or 
allergic disease (including drug allergies, but excluding untreated, as ymptomatic, 
seasonal allergies at the time of dosing ).
2.Positive test result for SARS -CoV -2 infection at the time of Screening or Day  -1.
3.History  of HIV infection, hepatitis B, or hepati tisC; positive testing for HIV, HBsAg, 
or HCVAb. Hepatitis B vaccination is allowed.
4.Other medical or psy chiatric condition including recent (within the past y
ear) or 
active suicidal ideation /behavior or laboratory  abnormality  or other conditions or 
situa tions related to COVID -19 pandemic (eg ,Contact [CONTACT_216478], residence, 
or travel to an area with high incidence) that may  increase the risk 
ofstudy 
participation or , in the investigator’s judgment, make the participant inappropriate for 
thestudy .
5.History  of thrombotic events.
Prior/Concomitant Therapy:
6.Use of prescription or nonprescription drugs and dietary and herbal supplements 
within 7 days or 5 half-lives (whichever is longer) prior to the first dose of study  
intervention . (Refer to Section 6.8 Concomitant Therap y for additional details ).
7.Systemic therapy  with any  medications that are strong CYP3A4 inhibitors within 28 
days or 5 half -lives (whichever is longer) or strong CYP3A inducers within 28 day s 
or 5 half -lives (whichever is longer) prior to dosing of study  intervention 
8.Current use of any prohibited concomitant medication(s) or those unwilling/unable to 
use a pe rmitted concomitant medication(s). Refer to Section 6.8 Concomitant 
Therap y.
Prior/Concurrent Clinical Study Experience:
9.
Previous administration with an investigational drug within 30 days (or as determined 
by [CONTACT_19970]) or 5half-
lives preceding the first dose of study  intervention
used in this study (whichever is longer). 

PF-[ADDRESS_1066794] 2 weeks; and /or 
participants who are scheduled to receive a second COVI D-19 vaccination dose 
during the in- clinical period of this study .
Diagnostic Assessments:
11.A positive urine drug test .
12.Screening supi[INVESTIGATOR_30991] >140mmHg (s ystolic) or >90mmHg (diastolic), following at 
least [ADDRESS_1066795]. If BP is >140 mmHg (s ystolic) or > 90mmHg 
(diastolic), the BP should be repeated 2 more times and the average of the 3 BP 
values should be used to determine the participant ’s eligibility .
13. S tandard 12-lead ECG thatdemonstrates clinically relevant abnormalities thatmay
affect participant safety or interpretation of study results (eg, baseline QTc Finterval
>[ADDRESS_1066796]- degree AVblock, or serious brady arrhy thmias or tachy arrhy thmias). If the 
baseline uncorrected QT interval is >450 msec, this interval should be rate -corrected 
using the Frideric ia method and the resulting QTcF should be used for decision 
making and reporting. If QTc Fexceeds 450 msec, or QRS exceeds 120 msec, the 
ECG should be repeated 2 more times and the average of the 3 QTcFor QRS values 
should be used to determine the participant’s eligibility .Computer -interpreted ECGs 
should be overread b y a physician experienced in reading ECGs before excluding a 
participant.
14.Participant s with ANY of the following abnormalities in clinic al laboratory tests at 
screening, as assessed b y the study -specific laboratory  and confirmed b y a single 
repeat test, if deemed necessary :
AST or ALT level ≥ 1.0 × ULN;
Total bilirubin level ≥1.5 × ULN; participants with a history of Gilbert's 
syndrome may have direct bilirubin measured and would be eligible for this study  
provided the direct bilirubin level is≤ ULN ;
Estimated glomerular filtration rate (eGFR) < 70 mL/min/1.73 m2based on the 
Chronic Kidney  Disease Epi[INVESTIGATOR_776758] .
Other 
Exclusions:
15.Total 14C radioactivity  measured in plasma exceeding 11 mBq/mL at “Screening ” .
16.Females who are breastfeeding. 

PF-[ADDRESS_1066797] 2021
PFIZER CONFIDENTIAL
Page 2817.History  of alcohol abuse or binge drinking and/or any  other illicit drug use or 
dependence within 6 months of Screening. Binge drink ing is defined as a pattern of 
5(male) and 4 (female) or more alcoholic drinks in about 2 hours . As a general rule, 
alcohol intake should not exceed 14units per week (1 unit=
8ounces (240 mL) beer, 
1ounce (30 mL) of 40% spi[INVESTIGATOR_107060] 3 ounces (90 mL) of w ine).
18.History  of tobacco or nicotine use within 3 months prior to dosing, or a positive 
cotinine at screening or Day -1.
19.Blood donation (excluding plasma donations) of approximately  1pi[INVESTIGATOR_11731] (500 mL)or 
more within 60days prior to dosing .
20.History  of sensitivity  to heparin or heparin -induced thrombocy topenia .
21.Unwilling or unable to comply  with the criteria in the Lifesty le Considerations
section of this protocol
.
22.Participants with a history of irregular bow el movements eg, less than 1 bowel 
movement per day , regular epi[INVESTIGATOR_457921], irritable bowel 
syndrome (IBS) or lactose intolerance.
23.Participants enrolled in a previous radionucleotide study  or who have received 
radiotherap y within 12 months prior to screening or such that total radioactivity  
would exceed acceptable dosimetry  (ie, occupational exposure of 5 rem per y ear).
24.Participants whose occupation requires exposure to radiation or monitoring of 
radiation exposure.
25.Investigator site staff or [COMPANY_007] employ ees directl y involved in the conduct of the 
study , site staff otherwise supervised by  [CONTACT_093], and their respective family  
members .
26. Previous exposure to PF- 07304814.
5.3.Lifestyle Considerations
The following guidelines are provided:
5.3.1. Meals and Dietary Restrictions
Participant s must abstain from all food and drink (except water) at least 4 hours prior 
to any  safety laboratory  evaluations and 10 hours prior to the collection of the predose 
PK sample.
Water may  be consumed without restriction. Noncaffeinated drinks (except grapefruit 
or grapefruit -related citrus fruit juices—see below) may  be consumed with meals and 
the evening snack .  

PF-[ADDRESS_1066798] 2021
PFIZER CONFIDENTIAL
Page 29Lunch will be provided approximately  4hours after the start of infusion .
Dinner will be provided approximately  9to 10 hours after the start of infusion .
An evening snack may be permitted .
Participants will refrain from consuming red wine, grapefruit, or grapefruit -related 
citrus fruits (eg, Seville oranges or pomelos) from [ADDRESS_1066799] dose of 
study  intervention until collection of the final PK blood sample.  
While participants are confined, the irtotal daily  nutritional composition should be 
approximately  55% carbohy drate, 30% fat ,and 15% protein. The dail y caloric intake 
per particip antshould not exceed approximately  3200 kcal.
To help assure regularit y in bowel movements, nutritional composition should 
contain at least 15 g of fiber per 1000 kcal or fiber capsules containing the equivalent 
amount of fiber may  be administered daily  (beginning at least 8 h ours after dosing).
If an individual participant has not experienced a bowel movement within 36 hours of 
their previous bowl movement, fluid intake should be increased and administration of 
a mild laxative (eg, prune juice or a mild stool softener) should be implemented, with
the goal to facilitate at least 1daily  bowel movement. The use of laxative should be 
recorded.
Participants will be asked to abstain from indigestible materials, eg, corn, nuts, etc, 
for 2 day s prior to dosing and for the duration of the study  in order to facilitate fecal 
homogenization.
5.3.2. Caffeine, Alcohol, and Tobacco
Participant s will abstain from caffeine -containing products for 24 hours prior to the 
start of dosing until collection of the final PK sample is collected .  
Participant s will abstain from alcohol for [ADDRESS_1066800] at the discretion of the 
investigator.
Participant s will abstain from the use of tobacco -or nicotine -
containing products for 
3months prior to dosing and during confinement in the CRU.
5.3.3. Activity
Participants will abstain from strenuous exercise (eg, heav y lifting, weight training, 
calisthenics, aerobics) for at least 48 hours prior to each blood collection for clinical 
laboratory  tests. Walking at a normal pace will be permitted ;

PF-[ADDRESS_1066801] 2021
PFIZER CONFIDENTIAL
Page 305.3.4. Contraception
The investigator or his or her designee, in consultation with the participant , will confirm that 
the participant has selected an appropriate method of contraception for the individual 
participant and his or her partner(s) from the permitted list of contraception methods (see 
Appendix 4)and will confirm that the participant has been instructed in its consistent and 
correct use. At time points indicated in the schedule of activities ( SoA), the investigator or 
designee will inform the participant of the need to use highly effective contraception 
consistently  and correctly  and document the conversation and the participant’s affirmation in 
the partic ipant ’s chart ( participant s need to affirm their consistent and correct use of at least 1 
of the selected methods of contraception) considering that their risk for pregnancy  may  have 
changed since the last visit . In addition, the investigator or designee w ill instruct the 
participant to call immediately  if the selected contraception method is discontinued or if 
pregnancy  is known or suspected in the participant or partner.
5.4.Screen Failures
Screen failures are defined as participants who consent to participat e in the clinical study  but 
are not subsequently  enrolled in the study . A minimal set of screen failure information is 
required to ensure transparent reporting of screen failure participants to meet the CONSORT 
publishing requirements and to respond to queries from regulatory  authorities. Minimal 
information includes demograph y, screen failure details, eligibility  criteria, and any  SAE.
Screen failures are defined as participants who consent to participate in the clinical study  but 
are not subsequently  enrolled in the study . Screen failure data are collected and remain as 
source and are not reported on the CRF .
Individuals who do not meet the criteria for participation in this study  (screen failure) may be 
rescreened. 
6.STUDY INTERVENTION(S) AND CONCOMITA NT THERAPY
Study  intervention is defined as any  investigational intervention(s), marketed product(s), 
placebo, medical device(s) , or study  procedure(s) intended to be administered to a study  
participant according to the study  protocol.
For the purposes of this protocol, study  intervention refers to PF-
07304814, administered as a 
single, 24
-hour constant -rate, continuous IV infusion of 500 mg containing approximately  
420nCi [14C] PF -
07304814.
6.1.Study Intervention(s) Administered
[14C]PF-
07304814 will be provided b y [COMPANY_007] as bulk API  [INVESTIGATOR_1238], where necessary , bulk 
excipi[INVESTIGATOR_776759] [14C] labeled IV formulation. The final product 
composition , sourcing of components and/or excipi[INVESTIGATOR_840], andpresentation will be detailed in a 
separate T echnical Agreement (TA) for IV drug product .

PF-[ADDRESS_1066802] 2021
PFIZER CONFIDENTIAL
Page 316.1.1. Administration
Participant s will receive 500 mg PF -07304814 containing approximately  420nCi 
[14C]PF-07304814 starting at approximately  08:00hour (plus or minus 2 hours) , 
administered as a single, 24 -hour constant -rate, continuous IV infusion
. Administration of 
[14C]PF-07304814 will be performed b y qualified investigator site personnel (in accordance 
with local regulations and laws). Investigator site personnel will administer study  
intervention according to the site administration instructions (SAI) .
6.2.Preparation , Handling , Storage , and Accountability
1.
The investigator or designee must confirm appropriate temperature conditions have 
been maintained during transit for all study  intervention sreceived and an y 
discrepancies are reported and resolved before use of the study  intervention. 
2.Only  participants enrolled in the study  may  receive study  intervention and only  
authorized site staff may  supply  or administer study  intervention. All study  
interventions must be stored in a secure, environmentally  controlled, and monitored 
(manual or automated recording) area in accordance with the labeled storage 
conditions with access limited to the investigator and authorized site staff. At a 
minimum, daily  minimum and maximum temperatures for all site storage locations 
must be documented and available upon request. Data for nonworking day s must 
indicate the minimum and maximum temperature ssince previousl y documented for 
all site storage locations upon retur n to business .
3.Any excursions from the study  intervention label storage conditions should be 
reported to [COMPANY_007] upon discovery  along with an y actions taken. The site should 
activel y pursue options for returning the stud y intervention to the storage conditi
ons 
described in the labeling, as soon as possible. Once an excursion is identified, the 
study  intervention must be quarantined and not used until [COMPANY_007] provides permission 
to use the study  intervention. Specific details regarding the definition of an exc ursion 
and information the site should report for each excursion will be provided to the site 
in a separate TA .
4.Any storage conditions stated in the SRSD will be superseded by  [CONTACT_78254].
5.Study  interventions should be stored in their original containers.
6.The investigator, institution, or the head of the medical institution (where applicable) 
is responsible for stud y intervention accountability, reconciliation, and record 
maintenance (ie, receipt, reconciliation, and final dis position records) , such as the 
IPAL or sponsor -approved equivalent .All study  intervention s will be accounted for 
using a study  intervention accountabilit y form/record.

PF-[ADDRESS_1066803] complaint, notify the sponsor w ithin 1 business day  of 
discovery .
6.2.1. Preparation and Dispensing
Within this protocol, preparation refers to the investigator site activities performed to make 
the study  intervention ready  for administration or dispensing to the participant by [CONTACT_216479]. Dispensing is defined as th e provision of study  intervention , concomitant treatments, 
and accompan ying information by  [CONTACT_22806](s) to a healthcare provider, 
participant in accordance with this protocol. L ocal health authority  regulations or investigator 
site guidelines may use alternative terms for these activities.
[14C]PF -07304814 solution for the IV administration will be manufactured at the clinical 
study  site by  2 trained personnel and qualit y assurance (QA) released prior to administration. 
Details of the dose prep aration will be provided in a separate TA. Prepared doses will be 
provided in unit dose containers and labeled in accordance with [COMPANY_007] regulations and the 
investigator site’s labeling requirements. Leftover containers following IV administration, 
includi ng tubing used for infusion, should be shipped to laboratory  for assessment of 
radioactivity , if needed.
6.3.Measures to Minimize Bias: Randomization and Blinding
6.3.1. Allocation to Study I ntervention
The site staff will assign participant numbers to the participant s as they  are screened for the 
study . [COMPANY_007] will provide a randomization schedule to the investigator and, in accordance 
with the randomization numbers, the participant will receive the stud y treatment regimen 
assigned to the corresponding rand omization number.
6.4. Study Intervention Compliance
When participants are dosed at the site, they  will receive study  intervention directly  from the 
investigator or designee, under medical supervision. The date and time of each dose 
administered in the clinic w ill be recorded in the source documents and recorded in the CRF. 
The dose of stud y intervention and study participant identification will be confirmed at the 
time of dosing b y a member of the stud y site staff other than the person administering the 
study  intervention.

PF-[ADDRESS_1066804], which may  be detailed in the TA. It does not 
preclude the use of an existing appropriate clinical site documentation sy stem. The existing 
clinical site's documentation sy stem should capture all per tinent/required information on the 
preparation and administration of the dose. This may  be used in place of the Preparation 
Record after approval from the sponsor and/or designee.
6.5. Dose Modification
Not applicable.
6.6.Continued Access to Study Intervention 
After the End of the Study
No intervention will be provided to study  participants at the end of their study participation .
6.7.Treatment of Overdose
For this study , any  dose of PF -07304814 greater than 700mgwithin a 24-hour time period
will be considered an overdose.
There is no specific treatment for an overdose
.
In the event of an overdose, the investigator should:
1.Contact [CONTACT_22840] 24 hours.
2.Closely  monitor the participant for an y AEs/SAEs and laboratory  abnormalities for at 
least 5 half -lives or 28 calendar day s after the overdose of PF -07304814 (whichever 
is longer).
3.Document the quantit y of the excess dose as well as the duration of the overdose in 
the CRF.
4.Overdose is reportable to [COMPANY_007] Safety  only when associated with an SAE.
5.Obtain a blood sample for PK anal ysis within 1day from the date of the last dose of 
study  intervention if requested by  [CONTACT_7195] (determined on a case -by-case 
basis).
6.8.Concomitant Therapy
Use of prescription or nonprescription drugs and dietary  and he rbal supplements are 
prohibited within 7 days or 5 half-lives (whichever is longer) prior to the first dose of study  
intervention. L imited use of nonprescription medications that are not believed to affect 
participant safety  or the overall results of the s
tudy may  be permitted on a case -by-case basis 
following approval b y the sponsor .Acetaminophen/paracetamol may  be used at doses of 
≤1g/day .If an individual participant has not experienced a bowel movement within 36 hours 
of their previous bowel movements, administration of a mild laxative (eg, prune juice or a 
mild stool softener) may be used
, with the goal to facilitate at least 1daily  bowel movement .

PF-[ADDRESS_1066805] 2021
PFIZER CONFIDENTIAL
Page 34Use of strong CYP3A inhibitors and/or inducers within 28 day s or 5 half -lives (whichever is 
longer) prior to the first dose of investigational product or during the study  are prohibited .
All concomitant treatments taken during the study  must be recorded with indication, daily  
dose, and start and stop dates of administrati on. All participants will be questioned about 
concomitant treatment at each clinic visit.
Treatments taken within [ADDRESS_1066806] dose of study  intervention 
will be documented as concomitant treatments.
6.8.1. Rescue Medicine 
There is no rescue therapy to reverse the AEs observed with PF-07304814; standard medical 
supportive care must be provided to manage the AEs. 
7.DISCONTINUATION OF STUDY INTERVENTION A ND PARTICIPANT 
DISCONTINUATION/WITHDRAWAL
7.1.Discontinuation of Study Intervention
It may  be necessary  for a participant to permanently  discontinue study  intervention 
(definitive discontinuation)
.Reasons for discontinuation of study  intervention include (but
are not limited to) the following: AEs, Phy sician decision, withdrawal by  [CONTACT_4317] .
If study  intervention is definitively  discontinued, the participant will not remain in the study  
for further evaluation. See the SoA for data to be collected at the time of discontinuation of 
study  intervention.
7.1.1. ECG Changes
A participant who meets either 
bulleted criterion on a single ECG will have 2 additional 
ECGs measured and the average of the triplicate ECG readings recorded. If the average of 
triplicate ECG readings meets either of the bulleted criterion, the participant will be 
withdrawn from the study intervention after consultation with the investigator and sponsor. 
QTcF >500 msec.
Change from baseline: QTc F>60 msecand QTcF >450 msec .
If a clinically  significant finding is identified (including, but not limited to ,changes from 
baseline in QT cFafter enrollment ), the investigator or qualified designee will determine if 
the participant can continue in the study  and if any change in parti cipant management is 
needed. This review of the ECG printed at the time of collection must be documented. An y 
new clinicall y relevant finding should be reported as an AE.

PF-[ADDRESS_1066807] 2021
PFIZER CONFIDENTIAL
Page 357.2.Participant Discontinuation/ Withdrawal F rom the Study
A participant may  withdraw fro m the study  at an y time at his/her own request. Reasons for 
discontinuation from the study  include the following:
Refused further study  procedures ;
Lost to follow -up;
Death ;
Study  terminated by  [CONTACT_3211] ;
At the time of discontinuing from the stud y, if possible, an earl y discontinuation visit should 
be conducted
.See the SoA for assessments to be collected at the time of study  
discontinuation and follow- up and for an y further evaluations that need to be completed. 
If a participant withdraws from the study , he/she may  request destruction of any  remaining 
samples taken and not tested, and t he investigator must document any  such requests in the 
site study  records and notify  the sponsor accordingly .
If the participant withdraws from th e study  and also withdraws consent (see Section 7.2.1) 
for disclosure of future information , no further evaluations should be performed and no 
additional data should be collected. The sponsor may retain and continue to use any  data 
collected before such withdrawal of consent.
7.2.1. Withdrawal of Consent
Participant s who request to discontinue receipt of study  intervention will remain in the study  
and must continue to be followed for protocol -specified follow -
up procedures. The onl y 
exception to this is when a participant specificall y withdraws consent for any further contact 
[CONTACT_469473]. Participant s should notify  the investigator in writing of the decision to withdraw 
consent from future follow -up, whenever possible. The withdrawal of consent should be 
explained in detail in the medical rec ords b y the investigator, as to whether the withdrawal is 
only from further receipt of study  intervention or also from study  procedures and/or 
posttreatment study  follow -up, and entered on the appropriate CRF page. In the event that 
vital status (whether the participant is alive or dead) is being measured, publicly  available 
information should be used to determine vital status only  as appropriatel y directed in 
accordance with local law.
7.3.Lost to Fol lowup 
A participant will be considered lost to follow-up i f he or she repeatedl y fails to return for 
scheduled visits and is unable to be contact[INVESTIGATOR_530] b y the study  site.

PF-[ADDRESS_1066808] be taken if a participant fails to attend a required study  visit:
The site must attempt to contact [CONTACT_4538] r eschedule the missed visit as 
soon as possible . Counsel the participant on the importance of maintaining the 
assigned visit schedule and ascertain whether the participant wishes to and/or should 
continue in the study ;
Before a parti cipant is deemed lost to follow -up, the investigator or designee must 
make every  effort to regain contact [CONTACT_6635] (where possible, 3 telephone 
calls and, if necessary , a certified letter to the participant’s last known mailing 
address or local equivalent methods). Th ese contact [CONTACT_14316]’s medical record ;
Should the participant continue to be unreachable, he/she will be considered to have 
withdrawn from the study. 
8.STUDY ASSESSMENTS AND PROCEDURES
The investigator (or an appropriate delegate at the investigator site) must obtain a signed and 
dated ICD before performing an y stud y-specific procedures.  
Study  procedures and their timing are summarized in the SoA. Protocol waivers or 
exemptions are not allowed.
Safety  issues should be discussed with the sponsor immediately  upon occurrence or 
awareness to determine whether the participant should continue or discontinue study  
intervention.
Adherence to the stud y design requir ements, including those specified in the SoA, is essential 
and required for stud y conduct.
All screening evaluations must be completed and reviewed to confirm that potential 
participants meet all eligibility  criteria. The investigato r will maintain a screening log to 
record details of all participants screened and to confirm eligibility  or record reasons for 
screening failure, as applicable.
Participant s will be screened within 
42days prior to administration of the study  intervention
to confirm that they  meet the study  population criteria for the study . If the time between 
screening and dosing exceeds 42days as a result of unexpected delay s (eg, delay ed drug 
shipment), then participants do not require rescreening if the laboratory  results obtained prior 
to first dose administration meet eligibility  criteria.
A participant who qualified for this protocol but did not enroll from an earlier cohort/group 
may be used in a subsequent cohort/group without rescreening, provided laboratory  results 
obtained prior to the first dose administration meet eligibility  criteria for this study . In 
addition, other clinical assessments or specimen collections, eg, retained research sample, 
may be used without repeat collection, as appropriate.

PF-[ADDRESS_1066809] be informed of these incidents in a timely  manner.
Ifan IV catheter is utilized for blood sample collections, EC Gs and vital sign assessments 
(pulse rate andBP) should be collected prior to the insertion of the catheter .Blood samples 
for PK must not be taken from the same arm used for IV drug administration on the day  of 
drug infusion.
For samples being collected and shipped, detailed collection, processing, storage, and 
shipment instructions and contact [CONTACT_19987] .
The total blood sampling volume for individual participant s in this study  is approximately  
280mL rounded up to nearest 5 mL.The actual collection times of blood sampling may  
change. Additional blood samples may  be taken for safet y assessments at times specified b y 
[COMPANY_007], provided the total volume taken during the study does not exceed 500 mLduring an y 
period of 56 consecutive day s.
To prepare for stud y participation, participant s will be instructed on the information in the 
LifestyleConsiderations andConcomitant Therapy sections of the protocol.
8.1.Efficacy Assessments
Not applicable.
8.2.Safety Assessments
Planned time points for all safety  assessments are provided in the SoA.Unscheduled clinical 
laboratory  measurements may  be obtained at any  time during the stud y to assess any 
perceived safety  issues.
8.2.1.
Physical Examinations
A complete physical examination will include , at a minimum, head, ears, eyes, nose, mouth, 
skin, heart and lung examinations, ly mph nodes, and gastrointestinal, musculoskeletal, and 
neurological s ystems. 
A brief physical examination will include, at a minimum, assessments of general appearance, 
the respi[INVESTIGATOR_2866] s ystems, and participant -reported s ymptoms.
Physical examinations may  be conducted by  a ph ysician, trained ph ysician's assistant, or 
nurse practitioner as acceptable according to local regulation. 

PF-[ADDRESS_1066810] physical 
examination findings that are identified during the active collection period and meet the 
definition of an AE or SAE ( Appendix 3 ) must be reported according to the processes in 
Sections 8.3.1 to 8.3.3.
8.2.2. Vital Signs
Supi[INVESTIGATOR_394979] ’s arm supported at the level of the heart
, and 
recorded to the nearest mmHg after approximately [ADDRESS_1066811] . The same arm 
(preferabl y the dominant arm) will be used throughout the study
. BP should not be taken 
from the arm with an intrave nous infusion
(even if that is the dominant arm) .Participant s 
should be instructed not to speak during measurements.
The same properl y sized and calibrated BP cuff will be used to measure BP each time. The 
use of an automated device for measuring BP and pulse rate is acceptable; however, when 
done manuall y, pulse rate will be measured in the brachial/radial artery  for at least 
30seconds. When the timing of these measurements coincides with a blood collection, BP 
and pulse rate should be obtained prior to the nominal time of the blood collection.
Additional collection times, or changes to collection times, of BPand pulse rate will be 
permitted, as necessary, to ensure appropriate collection of safety  data.
[IP_ADDRESS]. Temperature
Temperature will be measured orall y.No eating, drinking, or smoking is allowed for 
[ADDRESS_1066812] 12-l ead E CGs utilizing limb leads (with a 10 second rh ythm strip) should be 
collected at times specified in the SoA section of this protocol using an ECG machine that 
automatically  calculates the heart rate and measures PR, QT, and QTc Fintervals and QRS 
complex . Alternative lead placement methodology using torso leads (eg, Mason- Likar) 
should not be used given the pot ential risk of discrepancies with ECGs acquired using 
standard limb lead placement. All scheduled ECGs should be performed after the participant
has rested quietl y for at least 5 minutes in a supi[INVESTIGATOR_2547]. 
To ensure safet y of the participant s, a qualif ied individual at the investigator site will make 
comparisons to baseline measurements. Additional ECG monitoring will occur if a) a 
postdose QTc Finterval is increased by  >60 msecfrom the baseline andis >450 msec; or 
b)an absolute QT cFvalue is >[ADDRESS_1066813] 2021
PFIZER CONFIDENTIAL
Page 39occurs, then 2 additional ECGs will be collected approximately  2to 4minutes apart and the 
average of the 3 taken to confirm the original measurement. If the QTc Fvalues from these 
repeated ECGs rema in above the threshold value, then the participant will be withdrawn.
If a) a postdose QTc Finterval remains >60msecfrom the baseline andis >450 msec; or b) 
an absolute QT value is >500 msecfor any  scheduled ECG for greater than 4 hours (or 
sooner , at the discretion of the investigator); or c) QTcFintervals get progressively longer, 
the participant should undergo continuous ECG monitoring . A cardiologist should be 
consulted if QTc F intervals do not return to less than the criteri alisted above after 8 hours of 
monitoring (or sooner ,at the discretion of the investigator).
In some cases, it may  be appropriate to repeat abnormal ECGs to rule out improper lead 
placement as contributing to the ECG abnormality. It is important that leads beplaced in th e 
same positions each time in order to achieve precise ECG recordings. If a machine -read QTc 
value is prolonged, as defined above, repeat measurements may  not be necessary  if a 
qualified medical provider’s interpretation determines that the QTcF values are in the 
acceptable range.
ECG values of potential clinical concern arelisted in Appendix 7.
8.2.4. Clinical Safety Laboratory Assessments
See Appendix [ADDRESS_1066814] any  
clinically  relevant changes occurring during the study  in the AE section of the CRF. 
Clinically  significant abnormal laboratory  findings are those which are not associ ated with 
the underl ying disease, unless judged by  [CONTACT_78259]'s condition.
All laboratory  tests with values considered clinically  significantl y abnormal during 
participation in the study  or within 5daysafter the last dose of study  intervention should be 
repeated until the values return to normal or baseline or are no longer considered clinically  
significant b y the investigator or medical monitor.
If such values do not return to normal/baseline with in a period of time judged reasonable b y 
the investigator, the etiology  should be identified and the sponsor notified.
See Appendix 6for suggested actions and follow -
up assessments in the event of potential 
drug-induc ed liver injury.

PF-[ADDRESS_1066815] will be performed 
after approximately  4 day s (ie,upon completion of 4 ×24 hours in house), or if they  develop 
COVID -19 like s ymptoms. Additional testing may be required by  [CONTACT_776770].
8.3.Adverse Events ,Serious Adverse Events , and Other Safety Reporting
The definitions of an AE and an SAE can be found in Appendix 3.
AEs may  arise from s ymptoms or other complaints reported to the investigator by  [CONTACT_2416] (or, when appropriate, b y a caregiver, surrogate, or the participant's legall y 
authorized representative), or they  may  arise from clinical findings of the Investigator or 
other healthcare providers (clinical signs, test results, etc.).
The investigator and an y qualified designees are responsible for detecting, documenting, and 
recording events that meet the definition of an AE or SAE and remain responsible to pursue 
and obtain adequate information both to determine the outcome and to assess whether the 
event meets the criteria for classification as an SAE or cau sed the participant to discontinue 
thestudy  intervention (see Section 7.1). 
During the active collection period as described in Section 8.3.1, e ach participant will be 
questi oned about the occurrence of AEs in a nonleading manner.
In addition, the investigator may  be requested by  [CONTACT_19989] y to obtain specific follow -
up 
information in an expedited fashion.
8.3.1. Time Period and Frequency for C ollecting AE and SAE Information
The time period for actively  eliciting and collecting AEs and SAEs (“active collection 
period”) for each participant begins from the time the participant provides informed consent, 
which is obtained before the participant ’s participation in the study  (ie, before undergoing 
any study -related procedure and/or receiving study  intervention ), through and including a 
minimum of [ADDRESS_1066816] SAE Report Form.
Investigators are not obligated to activel y seek information on AEsor SAE s after the 
participant has concluded study  participation . However, if the investigator learns of an y SAE, 
including a death, at an y time after a participant has completed the study , and he/she 
considers the event to be reasonabl y related to the study  interve ntion, the investigator must 
promptly  report the SAE to [COMPANY_007] using the CT SAE Report Form.
[IP_ADDRESS].
Reporting SAEs to [COMPANY_007] Safety
All SAEs occurring in a participant during the active collection period as described in 
Section 8.3.[ADDRESS_1066817] SAE Report Form immediately  upon 
awareness and under no circumstance should this exceed 24 hours, as indicated in 
Appendix 3. The investigator will submit any  updated SAE data to the sponsor within 
24 hours of it being available.
[IP_ADDRESS]. Recording Nonserious AEs and SAEs on the CRF
All nonserious AEs and SAEs occurring in a participant during the active collection period, 
which begins after obtaining informed consent as described in Section 8.3.[ADDRESS_1066818] to the CRF 
requirements as described in Section 5.4.
8.3.2. Method of Detecting AEs and SAEs
The method of recording, evaluating, and assessing causality  of AE sand SAE sand the 
procedures for completing and transmitting SAE reports are provided in Appendix 3.
Care will be taken not to introduce bias when detecting AEs and/or SAEs. Open -ended and 
nonleading verbal questioning of the participant is the preferred method to inquire about 
AEoccurrences.
8.3.3. Follow -
Up of AEs and SAEs
After the initial AE or SAE report, the investigator is required to proactively  follow each 
participant at subsequent visits/contacts. For each event, the inves tigator must pursue and 
obtain adequate information until resolution, stabilization, the event is otherwise explained, 
or the participant is lost to follow- up (as defined in Section 7.3).

PF-[ADDRESS_1066819] the safet y of participants and the safet y of a 
study  intervention under clinical investigation are met.
The sponsor has a legal responsibility  to notify  both the local regulato ry authority  and other 
regulatory  agencies about the safet y of a stud y intervention under clinical investigation. The 
sponsor will comply  with country -specific regulatory  requirements relating to safet y 
reporting to the regulatory  authorit y, IRBs/ECs, and investigators.
Investigator safety  reports must be prepared for S[LOCATION_003]R saccording to local regulatory  
requirements and sponsor policy  and forwarded to investigators as necessary .
An investigator who receives S[LOCATION_003]Rs or other specific safet y information (eg, summary  or 
listing of SAEs) from the sponsor will review and then file it along with the SRSD(s) for the 
study and will notify  the IRB/EC, if appropriate according to local requirements.
8.3.5. Environmental Exposure, Exposure During Pregnancy or Breastfeeding, a nd 
Occupational Exposure
Environmental exposure, occurs when a person not enrolled in the study  as a participant 
receives unplanned direct contact [CONTACT_216480]. Such exposure 
may or may  not lead to the occurrence of an AE or S AE. Persons at risk for environmental 
exposure include healthcare providers, famil y members, and others who may be exposed. An 
environmental exposure may  include exposure during pregnancy , exposure during 
breastfeeding, and occupational exposure.
Any such exposure to the study  intervention under study  are reportable to [COMPANY_007] Safet y 
within 24 hours of investigator awareness.
[IP_ADDRESS]. Exposure During Pregnancy
An EDP occurs if: 
A female participant is found to be pregnant while receiving or after discontinuing 
study intervention .
A male participant who is receiving or has discontinued study  intervention exposes a 
female partner prior to or around the time of conception . 

PF-[ADDRESS_1066820] 2021
PFIZER CONFIDENTIAL
Page 43A female is found to be pregnant while being exposed or having been exposed to 
study  intervention due to environmental exposure. Below are examples of 
environmental EDP : 
A female family  member or healthcare provider reports that she is pregnant after 
having been exposed to the study  intervention by [CONTACT_78262], inhalation, or skin 
contact .
A male famil y member or healthcare provider who has been exposed to the study  
intervention by  [CONTACT_78262], inhalation, or skin contact [CONTACT_240854] .
The investigator must report EDP to [COMPANY_007] Safety within 24 hours of the investigator’s 
awareness, irrespective of whether an SAE has occurred. The initial information submitted 
should include the anticipated date of delivery  (see below for information related to 
termination of pregnancy). 
If EDP occurs in a participant or a participant’s partner, the investigator must report 
this information to 
[COMPANY_007] Safety on the CT SAE Report Form and an EDP 
Supplemental Form, regardless of whether an SAE has occurred. Details of the 
pregnancy  will be collected after the start of study  intervention and until 28calendar 
days after the last dose .
If EDP occurs in the setting of environmental exposure, the investigator must report 
information to [COMPANY_007] Safety  using the CT SAE Report Form and EDP Supplemental 
Form. Since the exposure information does not pertain to the participant enrolled in 
the study , the information is not recorded on a CRF; however, a copy  of the 
completed CT SAE Report Form is maintained in the investigator site file.
Follow -upis conducted to obtain general information on the pregnancy  and its outcome for 
all EDP reports with an unknown outcome. The investigator will follow the pregnancy  until 
completion (or until pregnancy  termination) and notify  [COMPANY_007] Safet y of the outcome a sa 
follow -up to the initial EDP S upplemental Form. In the case of a live birth, the structural 
integrit y of the neonate can be assessed at the time of birth. In the event of a termination, the 
reason(s) for termination should be specified and, if clinical ly possible, the structural 
integrit y of the terminated fetus should be assessed by [CONTACT_4692] (unless 
preprocedure test findings are conclusive for a congenital anomal y and the findings are 
reported).
Abnormal pregnancy  outcomes are considere d SAEs. If the outcome of the pregnancy  meets 
the criteria for an SAE (ie, ectopic pregnancy , spontaneous abortion, intrauterine fetal 
demise, neonatal death, or congenital anomal y in a live -born bab y, a terminated fetus, an 
intrauterine fetal demise, or a neonatal death), the investigator should follow the procedures 
for reporting SAEs. Additional information about pregnancy  outcomes that are reported to 
[COMPANY_007] Safety  as SAEs follows: 

PF-[ADDRESS_1066821] 2021
PFIZER CONFIDENTIAL
Page 44Spontaneous abortion includ ingmiscarriage and missed abortion;
Neonata l deaths that occur within [ADDRESS_1066822] 
to causality , as SAEs. In addition, infant deaths after 1 month should be reported as 
SAEs when the investigator assesses the infant death as related or possibly  related to 
expo sure to the study  intervention. 
Additional information regarding the EDP may  be requested by  [CONTACT_456]. Further 
follow -up of birth outcomes will be handled on a case- by-case basis (eg, follow -up on 
preterm infants to identify developmental delay s). In the case of paternal exposure, the 
investigator will provide the participant with the Pregnant Partner Release of Information 
Form to deliver to his partner. The investigator must document in the source documents that 
the participant was given the Pregnant Partner Release of Information Form to provide to his 
partner.
[IP_ADDRESS]. Exposure During Breastfeeding
An exposure during breastfeeding occurs if: 
A female participant is found to be breastfeeding while receiving or after 
discontinuing study  intervention.
A female is found to be breastfeeding while being exposed or having been exposed to 
study  intervention (ie, environmental exposure). An example of environmental 
exposure during breastfeeding is a female family  member or healthcare provider who 
reports that she is breastfeeding after having been exposed to the study  intervention 
by [CONTACT_78262], inhalation, or skin contact .  
The investigator must report exposure during breastfeeding to [COMPANY_007] Safety  within 24 hours 
of the investigator’s awareness, irrespective of whether an SAE has occurred. The 
information must be reported using the CT SAE Report Form. When exposure during 
breastfeeding occurs in the setting of environmental exposure, the exposure information does 
not pertain to the participant enrolled in the study , so the information is not recorded on a 
CRF. However, a cop y of the completed CT SAE Report Form is maintained in the 
investigator site file.
An exposure during breastfeeding report is not created when a [COMPANY_007] drug specificall y 
approved for use in breastfeeding women (eg, vitamins) is administered in accord with 
authorized use. However, if the infant experiences an SAE associated with such a drug, the 
SAE is reported together with the exposure during breastfeeding.

PF-[ADDRESS_1066823] 2021
PFIZER CONFIDENTIAL
Page [IP_ADDRESS]. Occupational Exposure
The investi gator must report any  instance of occupational exposure to [COMPANY_007] Safet y within 
24
hours of the investigator’s awareness using the CT SAE Report Form regardless of 
whether there is an associated SAE. Since the information about the occupational exposure 
does not pertain to a participant enrolled in the study , the information is not recorded on a 
CRF; however, a cop y of the completed CT SAE Report Form must be maintained in the 
investigator site file .
8.3.6.
Cardiovascular and Death Events
Not applicable.
8.3.7. Disease -Related Events and/or Disease -Related Outcomes Not Qualifying as AEs 
or SAEs
Not applicable.
8.3.8. Adverse Events of Special Interest
Adverse events of special interest (AESIs) are examined as part of routine safet y data review 
procedures throughout the clinical trial and as part of signal detection processes.
All AESI s must be reported as an AE or SAE following the procedures described in 
Section 8.3.[ADDRESS_1066824] SAE Report Form.
[IP_ADDRESS]. Lack of Efficacy
This section is not applicable because efficacy  is not expected in the study  population.
8.3.9. Medical Device Deficiencies
Not applicable.
8.3.10. Medication Errors
Medication errors may  result from the administration or consumption of the study  
intervention by [CONTACT_19995] , or at the wrong time, or at the wrong dosage strength.
Exposures to the study  intervention under stud y may occur in clinical trial set tings, such as 
medication errors.
Safety Event Recorded on the CRF Reported on the CT SAE Report 
Form to [COMPANY_007] Safety Within 
24 Hours of Awareness
Medication errors All (regardless of whether 
associated with an AE)Only  if associated with an SAE

PF-[ADDRESS_1066825] 2021
PFIZER CONFIDENTIAL
Page 46Medication errors include:
Medication errors involving participant exposure to the study  intervention ;
Potential medication errors or uses outside of what is foreseen in the protocol that do 
or do not involve the study participant .
The administration of expi[INVESTIGATOR_214312];
The administration of an incorrect study  intervention;
The administration of an incorrect dosage;
The administration of study  intervention that has undergone temperature excursion 
from the specified storage range, unless it is d etermined by  [CONTACT_214348].
Such medication errors occurring to a stud
y participant are to be captured on the medication 
error page of the CRF, which is a specific version of the AE page.
In the event of a medication dosing error, the sponsor should be notified within 24 hours .
Whether or not the medication error is accompanied by  [CONTACT_1149], as determined by  [CONTACT_1275], the medication error is recorded on the medication error page of the CRF and, if 
applicable, an y associated AE(s), serious and nonserious, are recorded on theAE page of the 
CRF.
Medication errors should be reported to [COMPANY_007] Safety within [ADDRESS_1066826] SAE Report 
Form only when associated with an SAE.
8.4.Pharmacokinetics , [14C] Assessmen t, and Metabolite Profiling
Details regarding the processing, storage, and shippi[INVESTIGATOR_776760] [14C] assessment samples 
will be provided in the lab manual.
Blood samples for measurement of p lasma concentrations of 
PF-07304814 and
PF-00835231 , plasma t otal [14C], and metabolic profiling will be collected as specified in the 
SoA. Urine and feces will be collected at the time windows spe cified in the SoA for total 
[14C] ex cretion, and mass -balance . All samples must be processed and shipped as indicated in 
the instructions provided in order to maintain sample integrit y
. Any deviations from the 
sample handling procedure (eg, sample collection and processing steps, interim storage or 
shippi[INVESTIGATOR_19944]), including an y actions taken must be documented and reported. On a 
case-by-case basis, the S ponsor may  make a determination as to whether sample i ntegrit y has 
been compromised. The actual date and time (24 -hour clock time) of each sample wi ll be 
recorded.

PF-[ADDRESS_1066827] 2021
PFIZER CONFIDENTIAL
Page 47Details for measurements are provided in Sections 8.4.1, 8.4.2, 8.4.3 for plasma, urine, and 
feces, respectively. Complete details will be provided in the study manual. 
Any remaining plasma, urine, or feces samples may be retained and utilized to evaluate 
safety or efficacy aspects related to concerns arising during or after the study, for metabolite identification and/or evaluation of the bioanalytical method,
8.4.1. Plasma for Analysis
Blood samples will be collected for measurement of plasma concentrations of PF-07304814, 
PF-00835231, PF-07319509, and PF-03626560 (4 mL/samp le, split plasma sample to two 
aliquots), and total [
14C] (4mL/sample), as specified in the SoA. A single [ADDRESS_1066828] nominal time relative to dosing. Collection of samples up to and including 10 hours after dose administration that are obtained within 10% of the nominal time relative to dosing (eg, within 6 minutes of a 60-minute sample) will not be captured as a protocol deviation, as long as the exact time of the collection is noted on the source document and the CRF. Collection of samples more than 10 hours after doseadministration that are obtained ≤[ADDRESS_1066829] time of the collection is noted on the source document and the CRF. 
Samples collected for analyses of PF-07304814, PF-00835231, PF-07319509, and
PF-03626560 concentration may also be used to evaluate safety or efficacy aspects related to concerns arising during or after the study, for metabolite identification and/or evaluation of the bioanalytical method,
Genetic analyses will not be performed on these plasma samples unless consent for this was 
included in the informed consent. Participant confidentiality will be maintained.
Details regarding the collection, processing, storage and shippi[INVESTIGATOR_776761].
Samples collected for measurement of plasma concentrations of PF-07304814, PF-00835231, 
PF-07319509, and PF-03626560- will be analyzed using a validated analytical method in 
compliance with applicable SOPs. Samples collected for plasma [
14C] determination will be 
analyzed using AMS. Potential metabolites may be analyzed with validated
methods.CCI
CCI
CCI
CCICCI
CCI
PF-[ADDRESS_1066830] 
be documented and approve d by [CONTACT_185618], but will not constitute a protocol amendment. The I RB/EC will 
be informed of an y safety issues that require alteration of the safet y monitoring scheme or 
amendment o f the ICD.
8.4.2. Urine for Analysis
Urine will be collected for anal ysis of PF-07304814 and PF -00835231, total [14C] 
measurement, and metabolite identification within intervals specified in the SoA.
Each participant will empty  his bladder just prior to dosing. A 10 mL aliquot from this urine 
(urine “blank”) will be labeled and frozen at –20° C or lower . 
Urine samples will be collected post the start of infusion at voiding and labeled for the 
appropriate 24 -hour time period in which each sample has been collected. During the entire 
collection period, the urine container should be refrigerated. At the end of each urine 
collection period, the total weight will be measured and recorded. The urine within each 
collection interval will be mixed tho roughly and aliquoted to assess: 
Fraction of [14C] dose excreted in urine ;
PF-07304814 and PF- 00835231 ;
Metabolic profiling .
Following completion of anal yses and subsample collections for metabolite profiling, the 
remaining urine samples will be discarded upon approval from the sponsor.
Details regarding the collection volume, processing, storage and shippi[INVESTIGATOR_776762] s will be provided in the lab manual.
8.4.3. Feces Analysis
Feces will be collected for determination of total [14C] measurement and metabolite 
identification. Fecal voids will be collected within intervals specified in the SoA. Each 
partic ipant will be required to provide a fecal sample prior to dosing during the time period 
of Day  -1 to Day  1 predose. This entire fecal sample will be labeled as feces “blank” and will 
be frozen at 
–20°C or lower .Date, and time must be recorded.
Postdose fe cal voids will be collected from each bowel movement into ziploc bags, labeled 
for the appropriate 24 -hour time period in which each sample has been collected, and 
immediately  frozen at –20°C or lower . Once received at the lab, fecal samples will be pulled
for the appropriate 24 -hour interval and total fecal mass recorded for each 24 -hour period. 
Samples will then be homogenized and 2 fecal homogenate aliquots will be collected to 
assess: 

PF-[ADDRESS_1066831] 2021
PFIZER CONFIDENTIAL
Page 49Fraction of [14C] dose excreted in feces;
Metabolic profiling .
In the event of diarrhea during the study , all diarrhea, including any  swabbing and 
contaminated linen, should be collected, labeled, and stored in appropriate containers 
at -20°C or lower for possible analy sis of [14C]. Following completion of analysis and 
subsample collections for metabolite profiling, the remaining bulk fecal homogenate will be 
discarded upon approval from the sponsor.
Details regarding the collection, processing, storage and shippi[INVESTIGATOR_457928].
8.5.Genetics
8.5.1. Specified Genetics
Genetics (specified anal yses) are not evaluated in this study . 
8.5.2. Retained Research Samples for Genetics
A 4-mL blood sample optimized for DNA isolation Prep D1 will be collected according to 
the SoA ,as local regulations and I RBs/ECs allow.
Retained Research Samples may be used for research related to thestudy  intervention (s). 
Genes and other analy tes (eg ,proteins, RNA, nondrug metabolites) may  be studie d using the 
banked samples. 
See Appendix 5for i
nformation regarding genetic research. Details on processes for 
collection and shipment of these samples can be found in supporting documentation. 
8.6.Biomarkers
Biomarkers are not evaluated in this study .
8.6.1. Specified Gene Expression (RNA) Research 
Specified gene expression (RNA) research is not included in this study .
8.6.2. Specified Protein Research
Specified protein research is not included in this study .
8.6.3. Specified Metabolomic Research 
Specified metabolomic research is not included in this study .
8.6.4. Retained Research Samples for Biomarkers
Retained research samples for biomarkers will be not be collected in this study .

PF-[ADDRESS_1066832] 2021
PFIZER CONFIDENTIAL
Page 508.7.Immunogenicity Assessments
Immunogenicit y assessments are not included in this study .
8.8.Health Economics
Health e conomics/ medical resource utilization and health e conomics parameters are not 
evaluated in this study .
9.STATISTICAL CONSIDERATIONS
Detailed methodology  for summary  and statistical anal ysesof the data collected in this study  
is outlined here and further detailed in a SAP, which will be maintained b y the sponsor. The 
SAP may  modify  what is outlined in the protocol where appropriate; however, any  major 
modifications of the primary  endpoint de finitions or their anal yses will also be ref lected in a 
protocol amendment.
9.1.Statistical Hypotheses
There is no formal research hy pothesis to be statistically  tested for this study . 
9.2.Analysis Sets
For purposes of analy sis, the following 
analysis sets are defined:
Participant Analysis Set Description
Enrolled /Randomly  
assigned to stud y 
intervention"Enrolled" means a participant's, or their legall y authorized 
representative’s, agreement to participate in a clinical study  
following completion of the informed consent process and 
screening . Potential participants who are screened for the 
purpose of determining eligibility  for the stud y, but do not 
participate in the stud y, are not considered enrolled, unless 
otherwise specified b y the protocol. A partic ipant will be 
considered enrolled if the informed consent is not withdrawn 
prior to participating in any  study  activity  after screening.
Full Anal ysis Set (FAS) Example: All participants assigned to stud y intervention and 
who take stud y intervention.
Safety Anal ysis Set All participants assigned to study  intervention and who take at 
least [ADDRESS_1066833] one measurable PF-07304814 and PF- 00835231 
concentration.
The PK concentration analy sis set for [14C] is defined as all 
participants who receive study  intervention and have at least 
one [14C] measurement.

PF-[ADDRESS_1066834] 
evaluable total [14C] concentration (urinary and fecal) data and 
who had no protocol deviations or AEs (such as diarrhea or 
severe constipation) that may  have affected the mass balance 
analysis.
9.3. Statistical Analyses
The SAP will be developed and finalized before any anal yses are pe rformed and will 
describe the anal yses and procedures for accounting for missing, unused, and spurious data. 
This section is a summary of the planned statistical an alyses of the primary  and secondary  
endpoints.
9.3.1. Pharmacokinetic Analysis
[IP_ADDRESS]. Mass Balance
Carbon-14 in urine will be measured using accelerator mass spectrometry  and reported as the 
percentage of the administered dose of [14C]excreted at each time interval and as the total 
percent of dose excreted in urine.
Carbon- 14 in feces will be measured using accelerator mass spectrometry and reported as the 
percentage of the administered dose of [14C]excreted at each time interval and as the total 
percent of dose excret ed in feces.
Percent recovery  of total [14C]in urine and feces will be determined based on total 
administered dose.
Individual participant and median data profiles will be graphicall y presented for the 
cumulative recovery  of [14C]in urine, feces and thei r combination. The total recovery  of 
[14C]in urine, feces and their combination will be listed and summarized. Where possible the 
rate of excretion of [14C]will be estimated.
[IP_ADDRESS]. Derivation of Pharmacokinetic Parameters (Plasma)
Plasma PF-07304814 and PF-00835231 (active moiety )concentrations will be reported in 
units of mass per volume, while total [14C]in plasma will be reported in units of unchanged 
drug concentration equivalents per volume ( eg,ngEq /mL). PK parameters ( Table 1) will be 
derived from 
PF-07304814 and PF -00835231 concentrations in plasma and from total [14C]
concentration equivalents in plasma. Actual PK sampling times will be used for the 
derivatio n of PK parameters. 
The PF-07304814 and PF -
00835231 concentrations and PK parameters and the total [14C]
concentration equivalents and PK parameters will be listed and summarized using descriptive 
statistics. I ndividual and median PF-07304814 and PF -
00835231 concentration -time profiles 
and total [14C]concentration equivalents -
time profiles will be graphicall y presented. 

PF-[ADDRESS_1066835] 
occurrence
C24 Obsereved plasma concentration at 24 hours Observed directly from data
t½aTerminal elimination half-life Log e(2)/k el, where k elis the terminal phase 
rate constant calculated by a linear regression 
of the log-linear concentration-time curve.
AUC lastaArea under the concentration-time profile 
from time zero to the time of the last quantifiable concentration (C
last)Linear/log trapezoidal method
AUC infaArea under the concentration-time profile 
from time zero extrapolated to infinite timeAUC last+ (C last*/k el), where C last* is the 
predicted plasma concentration at the last quantifiable time point estimated from the 
log-linear regression analysis.
CLa,bSystemic clearance Dose/AUC inf
Vssa,bSteady-state volume of distribution following 
IV infusionVss=CL × [MRT-(infusion time/2)]
where MRT is the Mean Residence Time and is calculated as AUMC
inf/AUC inf
a. If data permit
b. PF-07304814 only
PK samples will be stored and may be used in the future for 
scientific purpose, as needed.
[IP_ADDRESS]. Derivation of Pharmacokinetic Parameters (Urine)
Data permitting, following urine parameters will be calculated.
Parameter Definition Method of Determination
Total [14C] Urine Total cumulative [14C] excreted into
urine from time zero to the time of
last measurable concentration
following intravenously administered
[14C] PF-07304814 microtracer doseDirectly from observed [14C] data
%[14C] Urine % of [14C] in the urine
following IV administrationexpressed as a percent of the[
14C] dose administered(Total [14C]Urine/[14C] Dose iv) *100 where,
[14C] Dose ivis [14C] intravenously
administered dose of [14C] PF-07304814
Ae (PF-00835231) Amount of unchanged drug excreted 
in urineSum of [PF-00835231 urine concentration * 
sample volume] for each collection interval
Ae% (PF-00835231) Percent of PF-00835231 recovered
unchanged in urineAe/Dose*100CCI
CCI
PF-[ADDRESS_1066836] 2021
PFIZER CONFIDENTIAL
Page 53Total urine [14C]concentrations andpercent [14C]will be listed and summarized using 
descriptive statistics. Individual and summary  profiles of urine [14C]will be graphicall y 
presented.
[IP_ADDRESS]. Metabolic Profiling and Metabolite Identification
Plasma, urine, and fecal samples will be anal yzed for identification of metabolites of 
PF-07304814, if possible . Results of the metabolic profiling anal ysis will be detailed in a 
separate report and will be summarized in the CSR. 
9.3.2. Other 
Safety Analyses
All safet y anal yses will be performed on the s afety population.
AEs, ECGs, 
BP, pulse rate , and safety  laboratory  data will be reviewed and summarized on 
an ongoing basis during the study  to evaluate the safet y of participant s. An y clinical 
laboratory , ECG, BP, and pulse rate abnormalities of potential clinical concern will be 
described. Safet y data will be presented in tabular and/or graphical format and summarized 
descriptivel y, where appropriate.
Medical history  and phy sical examination an
d neurological examination information , as 
applicable, collected during the course of the study  will be considered source data and will 
not be required to be reported, unless otherwise noted. However, an y untoward findings 
identified on phy sical and/or neurological examination s conducted during the active 
collection period will be captured as AEs, if those findings meet the definition of an AE. 
Data collected at screening that areused for inclusion/exclusion criteria, such as laboratory  
data, ECGs ,and vit al signs , will be considered source data, and will not be required to be 
reported , unless otherwise noted. Demographic data 
(including participant race, ethnicity , 
age, and gender) collected at s creening will be reported .
[IP_ADDRESS]. Electrocardiogram Analyses
Changes from baseline for the ECG parameters QT interval, heart rate, QTc Finterval, PR 
interval, and QRS complex will be summarized by [CONTACT_22841].
The number (%) of participants with maximum postdose QTc Fvalues and maximum 
increases from baseline in the following categories will be tabulated by  [CONTACT_3148]: 
Safety QTc FAssessment
Degree of Prolongation Mild (msec) Moderate (msec) Severe (m sec)
Absolute value >450-480 >480-500 >500
Increase from baseline 30-60 >[ADDRESS_1066837] 2021
PFIZER CONFIDENTIAL
Page 549.3.3. Other Analyse (s)
Pharmacogenomic or biomarker data from Retained Research Samples may be collected 
during or after the trial and retained for future analyses; the results of such anal yses are not 
planned to be included in the CSR.
9.4.Interim 
Analyses
No formal interim analysis will be conducted for this study . As this is an open- label 
study ,the sponsor may  conduct unblinded reviews of the data during the course of the study  
for the purpose of safet y assessment, facili tating PK/PD modeling, and/or support ingclinical 
development .
9.5.Sample Size Determination
A sample size of 4 participants is considered the minimum sample size for 
mass -balance/ADME studies which include assessment of metabolic profiling. The sample 
size is not based on empi[INVESTIGATOR_776746]. A pproximately
5participants will be enrolled to study  intervention such that approximately [ADDRESS_1066838] 2021
PFIZER CONFIDENTIAL
Page 5510. SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS
10.1. Appendix 1: Regulatory, Ethical, and Study Oversight Considerations
10.1.1. Regulatory and Ethical Considerations
This study  will be conducted in accordance with the protocol and with the following:
Consensus ethical principles derived from international guidelines , including the 
Declaration of Helsinki and CI OMS International Ethical Guidelines ;
Applicable ICH GCP guidelines;
Applicable laws and regulations, including applicable privacy  laws .
The protocol, protocol amendments, I C
D, SRSD(s) , and other relevant documents 
(eg,advertisements) must be 
reviewed and approved by  [CONTACT_456] ,submitted to an I RB/EC 
by [CONTACT_093], and reviewed and approved by  [CONTACT_1201]/ EC before the study  is initiated.
Any amendments to the protocol will require IRB/EC approval before implementation of 
changes made to the study design, except for changes necessary  to eliminate an immediate 
hazard to study  participants.
Protocols and an y substantial amendments to the protocol will require health authority  
approval prior to initiation except for changes necessary to eliminate an immediate hazard to 
study  participants.
The investigator will be responsible for the following:
Providing written summaries of the status of the study  to the IRB/EC annually  or 
more frequently  in accordance with the requirements, policies, and procedures 
established by  [CONTACT_1201]/EC ;
Notify ing the IRB/EC of SAEs or other significant safet y findings as required by 
[CONTACT_1744]/EC procedures ;
Providing oversight of the conduct of the stud y at the site and adherence to 
requirements of 21 CFR, ICH GCP guidelines, the I RB/EC, European regulation 
536/2014 for clinical studies (if applicable), European Medical Device Regulation 
2017/745 for clinical device research (if applicable), and all other applicable local 
regulations .
[IP_ADDRESS]. Reporting of Safety Issues and Serious Breaches of the Protocol or ICH GCP
In the event of an y prohibition or restriction imposed (ie, clinical hold) b y an applicable 
regulatory  authorit y in any area of the world, or if the investigator is aware of an y new 
information that might influence the evaluation of the benefits and risks of the study  
intervention , [COMPANY_007] should be informed immediately .  

PF-[ADDRESS_1066839], and 
of an y serious breaches of this protocol or of the ICH GCP guidelines that the investigator 
becomes aware of.
10.1.2. Financial Disclosure
Investigators and subinvestigators will provide the sponsor with sufficient, accurate fin ancial 
information as requested to allow the sponsor to submit complete and accurate financial 
certification or disclosure statements to the appropriate regulatory  authorities. I nvestigators 
are responsible for providing information on financial interests during the course of the stud y 
and for 1 year after completion of the study .
10.1.3. Informed Consent Process
The investigator or his/her representative will explain the nature of the study , including the 
risks and benefits, to the participant and answer all quest ions regarding the study .The 
participant should be given sufficient time and opportunity  to ask questions and to decide 
whether or not to participate in the trial.
Participants must be informed that their participation is voluntary . Participants will be 
required to sign a statement of informed consent that meets the requirements of 21 CFR 50, 
local regulations, ICH guidelines, privacy  and data protection requirements, where 
applicable, and the IRB/EC or study  center.
The investigator must ensure that each study  participant is fully  informed about the nature 
and objectives of the study, the sharing of data related to the study ,and possible risks 
associated with participation, including the risks associated with the processing of the 
participant ’s personal data. 
The participant must be informed that his/her personal study -related data will be used by  [CONTACT_20004]. The level of disclosure must also be 
explained to the participant.
The participant must be informed th at his/her medical records may  be examined by  [CONTACT_160439], by  
[CONTACT_6667]/EC members, and b y inspectors from regulatory authorities.
The investigator further must ensure tha t each study  participant is fully  informed about his or 
her right to access and correct his or her personal data and to withdraw consent for the 
processing of his or her personal data.
The medical record must include a statement that written informed conse nt was obtained 
before the participant was enrolled in the study  and the date on which 
the written consent was 
obtained. The authorized person obtaining the informed consent must also sign the IC D.

PF-[ADDRESS_1066840] current versi on of the IC D(s) during their 
participation in the study .
A cop y of the IC D(s) must be provided to the participant.
A participant who is rescreened is not required to sign another IC Difthe rescreening occurs 
within 15days from the previous I CDsignature [CONTACT_568].
10.1.4. Data Protection
All parties will comply  with all applicable laws, including laws regarding the implementation 
of organizational and technical measures to ensure protection of participant data.
Participants’ personal data will be stored at the study  site in encry pted electronic form and 
will be password- protected to ensure that only authorized study  staff have access. The study  
site will implement appropriate technical and organizational measures to ensure that the 
personal data can be recov ered in the event of disaster. In the event of a potential personal 
data breach, the stud y site will be responsible for determining whether a personal data breach 
has in fact occurred and, if so, providing breach notifications as required by [CONTACT_2371].
To protec t the rights and freedoms of participants with regard to the processing of personal 
data, participants will be assigned a single, participant -specific numerical code. Any  
participant records or data sets that are transferred to the sponsor will contain the numerical 
code; participant names will not be transferred. All other identifiable data transferred to the 
sponsor will be identified by  [CONTACT_20007], participant-specific code. The study  site will 
maintain a confidential list of participant s who participat ed in the study , linking each 
participant ’s numerical code to his or her actual identity and medical record ID. In case of 
data transfer, the sponsor will protect the confidentiality  of participant s’ personal data 
consistent with the c linical study agreement and applicable privacy  laws.
10.1.5. Committees Structure
[IP_ADDRESS]. Data Monitoring Committee 
This study  will not use a DMC.
10.1.6. Dissemination of Clinical Study Data
[COMPANY_007] fulfills its commitment to publicly  disclose clinical study  results through posting the 
results of studies on www.clinicaltrials.gov (ClinicalTrials.gov), the EudraCT, and/or 
www.pfizer.com, and other public registries in accordance with applicable local 
laws/regulations. In addition, [COMPANY_007] reports study  results outside of the requirements of local
laws/regulations pursuant to its SOPs.
In all cases, stud y results are reported b y [COMPANY_007] in an objective, accurate, balanced, and 
complete manner and are reported regardless of the outcome of the stud y or the country in 
which the study  was conducted.

PF-[ADDRESS_1066841] 2021
PFIZER CONFIDENTIAL
Page 58www.clinicaltrials.gov
[COMPANY_007] posts clinical trial results on www.clinicaltrials.gov for [COMPANY_007]- sponsored interventional 
studies (conducted in patients) that evaluate the safety  and/or efficacy  of a product, 
regardless of the geographical location in which th e study  is conducted. These r esults are 
submitted for posting in accordance with the format and timelines set forth by  [CONTACT_20008].
EudraCT
[COMPANY_007] posts clinical trial r esults on EudraCT for [COMPANY_007] -sponsored interventional studies in 
accordance with the format and timelines set forth by  [CONTACT_20009].
www.pfizer.com
[COMPANY_007] posts public disclosure s ynopses (CSR synopses in which an y data that could be used 
to identify  individual participants have been removed) on www.pfizer.com for 
[COMPANY_007] -sponsored interventional studies at the same time the corresponding study  results are
posted to www.clinicaltrials.gov .
Documents within marketing authorization packages/submissions
[COMPANY_007] complies with the European Union Policy  0070, the proactive publication of clinical 
data to the EMA website. Clinical data, under Phase 1 of this policy ,includes clinical 
overviews, clinical summaries, C SRs, and appendices containing the protocol and protocol 
amendments, sample CRF s, 
and statistical methods. Clinical data, under Phase 2 of this 
policy ,includes the publishing of individual participant data. Policy  0070 applies to new 
marketing authorization applications submitted via the centrali zed procedure since 
01January 2015 and applications for line extensions and for new indications submitted via 
the centralized procedure since 
01 July  2015.
Data sharing
[COMPANY_007] provides researchers secure access to patient- level data or full CSRs for the purposes 
of “bona -fide scientific research” that contribute sto the scientific understanding of th e 
disease, target, or compound class. [COMPANY_007] will make data from these trials available 
24months after study  completion. Patient- level data will be anon ymized in accordance with 
applicable privacy  laws and regulations. CSRs will have personally  identifiab le information 
redacted.
Data requests are considered from qualified researchers with the appropriate competencies to 
perform the proposed analyses. Research teams must include a biostatistician. Data will not 
be provided to applicants with significant con flicts of interest, including individuals 
requesting access for commercial/competitive or legal purposes.

PF-[ADDRESS_1066842] 2021
PFIZER CONFIDENTIAL
Page 5910.1.7. Data Quality Assurance
All participant data relating to the study will be recorded on printed or electronic CRF unless 
transmitted to the sponsor or d esignee electronically  (eg, laboratory  data). The investigator is 
responsible for verify ing that data entries are accurate and correct by  [CONTACT_20010].
Guidance on completion of CRFs will be provided in the CRF Completion Re quirements 
document.
The investigator must ensure that the CRFs are securel y stored at the study site in encrypted 
electronic form and are password -protected to prevent access by  [CONTACT_20011].
The investigator must permit study -related monitoring, audits, IRB/EC review, and 
regulatory  agency  inspections and provide direct access to source data documents. This 
verification may  also occur after study  completion. I t is important that the investigator(s) and 
their relevant personnel are avai lable during the monitoring visits and possible audits or 
inspections and that sufficient time is devoted to the process.
Monitoring details describing strategy , including definition of study  critical data items and 
processes (eg, risk- based initiatives in operations and quality ,such as risk management and 
mitigation strategies and analytical risk-based monitoring), methods, responsibilities ,and 
requirements, including handling of noncompliance issues and monitoring techniques 
(central, virtual , or on- site monitoring) , are provided in the data management plan and 
monitoring plan maintained and utilized by  [CONTACT_36613].
The sponsor or designee is responsible for the data management of this study ,including 
quality  checking of the data.
Records and documents, including signed ICD s, pertaining to the conduct of this study  must 
be retained b y the investigator for 15years after study  completion unless local regulations or 
institutional policies require a longer retention period. No records may  be destroy ed during 
the retention period without the written approval of the sponsor. No records may  be 
transferred to another location or party without written notification to the sponsor. The 
investigator must ensure that the records continue to be stored s ecurel y for aslong as they  are 
maintained.
When participant data are to be deleted, the investigator will ensure that all copi[INVESTIGATOR_78245] y deleted from all systems.
The investigator(s) will notify  the sponsor or its agents immediately  of any  regulatory  
inspection notification in relation to the study . Furthermore, the investigator will cooperate 
with the 
sponsor or its agents to prepare the investigator site for the inspection and will allow 
the sponsor or its agent, whenever feasible, to be present during the inspection. The 
investigator site and investigator will promptly  resolve any  discrepancies that are identified 
between the stud y data and the participant's medical records. The investigator will pr omptly  
provide copi[INVESTIGATOR_19946]. Before response 

PF-[ADDRESS_1066843] maintain accurate documentation (source data) that supports the 
information entered in the CRF.
Study  monitors will perform ongoing source data verification to confirm that data entered 
into the CRF by  [CONTACT_325753], complete, and verifiable from source 
documents; that the safety and rights of participants are being protected; and that the study  is 
being conducted in accordance with the currently  approved protocol and any  other study  
agreements, I CH GCP guideli nes, and all applicable regulatory  requirements.
10.1.9. Study and Site Start and Closure
The study  start date is the date on which the clinical study  will be open for recruitment of 
participants.
The first act of recruitment is the date of the first participant’s first visit and will be the study  
start date.
The sponsor designee reserves the right to close the study  site or terminate the study  at any  
time for an y reason at the sole discretion of the sponsor. Study  sites will be closed upon study  
completion. A stud y site is considered closed when all required documents and study 
supplies have been collected and a stud y-site closure visit has been performed.

PF-[ADDRESS_1066844] 2021
PFIZER CONFIDENTIAL
Page 61The investigator may  initiate study -site closure at any  time upon notification to the sponsor 
or designee/ CRO if requested to do so by  [CONTACT_51025] I RB/EC or if such termination is 
required to protect the health of study  participants .
Reasons for the earl y closure of a stud y site b y the sponsor may include but are not limited 
to:
Failure of the investigator to comply  with the protocol, the requirements of the 
IRB/EC or local health authorities, the sponsor's procedures, or the ICH GCP 
guidelines ;
Inadequate recruitment of participants by  [CONTACT_093];
Discontinuation of further study  intervention development .
If the stud y is prematurely terminated or suspended, the sponsor shall promptly inform the 
investigators, the ECs/IRBs, the regulatory  authorities, and any  CRO (s) used in the study  of 
the reason for termination or suspension, as specified by  [CONTACT_20013]. The investigator shall promptly  inform the participant and should assure 
appropriate 
participant therapy  and/or follow -up.
Study  termination is also provided for in the clinical study  agreement. If there is any  conflict 
between the contract and this protocol ,the contract will control as to termination rights.
10.1.10. Publication Policy
The results of this study  may  be published or presented at scientific meetings b y the 
investigator after publication of the overall study  results or 1year after the end of the stud y 
(or study  termination), whichever comes first. 
The investigator agrees to refer to the primary  publication in any  subsequent publications ,
such as secondary manuscripts, and submit s all manuscripts or abstracts to the spons or 
30days before submission. This allows the sponsor to protect proprietary  information and to 
provide comments , and the investigator will, on request, remove an y previously undisclosed 
confidential information before disclosure, except for an y stud y-or [COMPANY_007] -intervention 
related information necessary  for the appropriate scientific presentation or understanding of 
the study  results.
For all publications relating to the stud y, the investigator will compl y with recognized ethical 
standards concerning publi cations and authorship, including those established by [CONTACT_19483].
The sponsor will comply  with the requirements for publication of the over all study  results 
covering all i nvestigator sites. In accordance with st andard editorial and ethical practice, the 
sponsor will support publication of multicenter studies only  in their entirety and not as 
individual site data. In this case, a coordinating investigator [INVESTIGATOR_78246].

PF-[ADDRESS_1066845] 2021
PFIZER CONFIDENTIAL
Page 62Authorship of publications for the overall study  results will be determined by  [CONTACT_78275] I nternational Committee of Medical Journal Editors authorship 
requirements. 
If publication is addressed in the clinical study agreement, the p ublication policy  set out in 
this section will not apply.
10.1.11. Sponsor’s Qualified Medical Personnel
The contact [CONTACT_1133]'s appropriately qualified medical personnel for the 
study  is documented in the study  contact [CONTACT_78276] (SToD) 
system.
To facilitate access to appropriatel y qualified medical personnel for study -related medical 
questions or problems, participants are provided with an Emergency  Contact [CONTACT_74057] (ECC) at 
the time of informed consent. The ECC contains , at a minimum, (a) protocol and study  
intervention identifiers, (b) participant’s stud y identification number, (c) site emergency 
phone number active 24 hours/day , 7 day s per week, and (d) [COMPANY_007] Call C enter number.
The ECC is intended to augment, not replace, the established communication pathway s 
between the investigator, site staff, and study  team. The ECC is to be used by  [CONTACT_78277] y only , as a means of reaching the investigator 
or site staff related to the care of a participant. The [COMPANY_007] Call Center number should only  be 
used when the investigator and site staff cannot be reached. The [COMPANY_007] Call Center number is 
not intended for use b y the participant directly ; ifa participant calls that number directl y, he 
or she will be directed back to the investigator site.

PF-[ADDRESS_1066846] 2021
PFIZER CONFIDENTIAL
Page 6310.2. Appendix 2: Clinical Laboratory Tests
The following safet y laboratory  tests will be performed at times defined in the SoA section of
this protocol. Additional laboratory  results may  be reported on these samples as a result of 
the method of anal ysis or the ty pe of anal yzer used by  [CONTACT_20019] ,or as derived 
from calculated values. These additional tests would not require add itional collection of 
blood. Unscheduled clinical laboratory  measurements may  be obtained at any  time during the 
study  to assess an y perceived safet y issues.
Table 2. Protocol -Required Safety Laboratory Assessments
Hem atology Chemistry Urinalysis Other
Hem oglobin
Hem atocrit
RBC count
MCV
MCH
MCHC
Platelet count
WBC count
Total neutrophils (Abs)
Eosinophils (Abs)
Monocytes (Abs)
Basophils (Abs)
Lymphocytes (Abs)
PT/INR/APTTBUN and creatinine
Glucose (fasting)
Calcium
Sodium
Potassium
Chloride
Total CO 2(bicarbonate)
AST, ALT
Total bilirubin
Alkaline phosphatase
Uric acid
Albumin
Total protein
eGFRaLocal Dipstick:
pH
Glucose (qual)
Protein (qual)
Blood (qual)
Ketones
Nitrites
Leukocyte esterase
Laboratory:
Microscopy and 
CulturebCOVID -19 testing
Urine drug testing
Urine cotinine testing
Urine alcohol testing
At screen ingonly:
Hepatitis B surface antigen
Hepatitis C antibody
Human immunodeficiency 
virus
FSH (females only)
a.eGFR will be calculated using equations below.
b.At PI [INVESTIGATOR_9106] .
CKD -EPI [INVESTIGATOR_10908]:
If female and SCr is ≤0.7 mg/dL :
GFR (mL/min/1.73 m2) = 144 × (SCr/0.7) –0.329 × 0.993age (× 1.159, if Black).
If female and SCr is >0.7 mg/dL :
GFR (mL/min/1.73 m2) = 144 × (SCr/0.7) – 1.209 × 0.993age (× 1.159, if Black).
If male and SCr is ≤0.9 mg/dL :
GFR (mL/min/1.73 m2) = 141 × (SCr /0.9) – 0.411 × 0.993age (× 1.159, if Black).
If male and SCr is >0.9 mg/dL :
GFR (mL/min/1.73 m2) = 141 × (SCr /0.9) – 1.209 × 0.993age (× 1.159, if Black).
The investigator must review the laboratory  report, document this review, and record any  
clinically  relevant changes occurring during the study in the AE section of the CRF.

PF-[ADDRESS_1066847] 2021
PFIZER CONFIDENTIAL
Page 64Any remaining serum/plasma from samples collected for clinical safety laboratory 
measurements at baseline and at all times after dose administration may be retained and stored for the duration of the study. Upon completion of the study, these retained safety samples may be used for the assessment of or unexpected safety findings. These data will not be included in the CSR. Samples to be used for this purpose will be shipped to either a [COMPANY_007]-approved BBS facility or other designated laboratory and retained for up to [ADDRESS_1066848] 2021
PFIZER CONFIDENTIAL
Page 6510.3. A ppendix 3: Adverse Events: Definitions and Procedures for Recording, 
Evaluating, Follow -Up, and Reporting
10.3.1. Definition of AE
AE Definition
An AE is an y untoward medical occurrence in a patient or clinical study 
participant, temporall y associated with the use of study  intervention, whether or not 
considered related to the study  intervention.
Note: An AE can therefore be an y unfavorable and unintended sign (including an 
abnormal laboratory  finding), s ymptom, or disease (new or exacerbated) 
temporally  associated with the use of stud y intervention.
Events Meeting the AE Definition
Any abnormal laboratory test results (hematology , clinical chemistry , or urinaly sis) 
or other safet y assessments (eg, ECG, radiological scans, vital sign measurements), 
including those that worsen from baseline, considered clinicall y significant in the 
medical and scientific judgment of the investigator. Any abnormal laboratory test 
results that meet an y of the conditions below must be recorded as an AE:
Is associated wit h accompany ing s ymptoms;
Requires additional diagnostic testing or medical/surgical intervention ;
Leads to a change in study  dosing (outside of any  protocol -specified dose 
adjustments) or discontinuation from the study , significant additional 
concomitant d rug treatment, or other therap y.
Exacerbation of a chronic or intermittent preexisting condition, including either an 
increase in frequency  and/or intensity  of the condition.
New condition detected or diagnosed after stud y intervention administration ,even
though it may  have been present before the start of the study .
Signs, sy mptoms, or the clinical sequelae of a suspected drug -drug interaction.
Signs, sy mptoms, or the clinical sequelae of a suspected overdose of either study  
intervention or a concomitant medication. Overdose per se will not be reported as 
an AE or SAE unless it is an intentional overdose taken with possible 
suicidal/self-harming intent. Such overdoses should be reported regardless of 
sequelae.

PF-[ADDRESS_1066849] 2021
PFIZER CONFIDENTIAL
Page 66Events NOT Meeting the AE Definition
Any clinically  significant abnormal laboratory  findings or other abnormal safet y 
assessments that are associated with the underl ying disease, unless judged by  [CONTACT_11009]’s condition.
The disease/disorder being studied or expected progression, signs, or s ymptoms of 
the disease/disorder being studied, unless more severe than expected for the 
participant’s condition.
Medical or surgical procedure (eg, endoscop y, appendectom y): the condition that 
leads to the procedure is the AE.
Situations in which an untoward medical occurrence did not occur (social and/or 
convenience admission to a hospi[INVESTIGATOR_307]).
Anticipated day -to-day fluctuations of preexisting disease(s) or condition(s) present 
or detected at the start of the study  that do not worsen.
10.3.2. Definition of an SAE
AnSAE is defined as any untoward medical occurrence that, at any dose, meets one 
or more of the criteria listed below:
a.Results in death
b.Is life -threatening
The term “life-threatening ”in the definition of “serious” refers to an event in which the 
participant was at risk of death at the time of the event. It does not refer to an event that
hypothetically  might have caused death if it were more severe.
c.Requires inpatient hospi[INVESTIGATOR_22770], hospi[INVESTIGATOR_12994] (usually  
involving at least an overnight stay ) at the hospi[INVESTIGATOR_19950]/or treatment that would not have been appropriate in the ph ysician’s office or 
outpatient setting. Complications that occur during hospi[INVESTIGATOR_1084] . If a 
complication prolongs hospi[INVESTIGATOR_9236], the event is 
serious. When in doubt as to whether “hospi[INVESTIGATOR_059]” occurred or was necessary , the 
AE should be considered serious.
Hospi[INVESTIGATOR_5187] a preexisting condition that did not worsen 
from baseline is not considered an AE.

PF-[ADDRESS_1066850] 2021
PFIZER CONFIDENTIAL
Page 67d.Results in persistent or significant disability/incapacity
The term disability means a substantial disruption of a person’s ability  to conduct 
normal life functions.
This definition is not intended to include experiences of relativel y minor medical 
significance , such as uncomplicated headache, nausea, vomiting, diarrhea, 
influenza, and accidental trauma (eg, sprained ankle), thatmay interfere with or 
prevent every day life functions but do not constitute a substantial disruption.
e.Is a congenital anomaly/birth defect
f.Is a suspected transmission via a [COMPANY_007] product of an infectious agent, pathogenic 
or non- pathogenic, is considered serious. 
The event may be suspected from clinical s ymptoms or laboratory  findings indicating 
an infection in a participant exposed to a [COMPANY_007] product. The terms “suspected 
transmission” and “transmission” are considered sy nony mous. These cases are 
considered unexpected and handled as seriou s expedited cases b y pharmacovigilance 
personnel. Such cases are also considered for reporting as product defects, if 
appropriate.
g.Other situations:
Medical or scientific judgment should be exercised by  [CONTACT_776771] i s appropriate in other situations, such as significant 
medical events that may jeopardize the participant or may  require medical or 
surgical intervention to prevent one of the other outcomes listed in the above 
definition. These events should usually  be co nsidered serious.
Examples of such events include invasive or malignant cancers, intensive treatment 
in an emergency  room or at home for allergic bronchospasm, blood dy scrasias or 
convulsions that do not result in hospi[INVESTIGATOR_059], or development of drug 
dependency  or drug abuse.
10.3.3. Recording/Reporting and Follow -Up of AE sand/or SAE sDuring the Active 
Collection Period
AE and SAE Recording /Reporting
The table below summarizes the requirements for recording AEs on the CRF and for 
reporting SAEs on the CT SAE Report Form to [COMPANY_007] Safet ythroughout the active 
collection period . These requirements are delineated for 3 ty pes of events: (1) SAEs; 
(2)nonserious AEs; and (3) exposure to the study  intervention under stud y during 
pregnancy  or breastfee ding, and occupational exposure. 

PF-[ADDRESS_1066851] SAE 
Report Form to [COMPANY_007] 
Safety Within 24 Hour s of 
Awareness
SAE All All
Nonserious AE All None
Exposure to the study  
intervention under stud y 
during pregnancy  or 
breastfeedingAll AEs/SAEs associated 
with exposure during 
pregnancy  or breastfeeding
Note: Instances of EDP or 
EDB not associated with an 
AE or SAE are not captured 
in the CRF.All instances of EDP are 
reported (whether or not 
there is an associated 
SAE)*
All instances of EDB are 
reported (whether or not 
there is an associated 
SAE).**
Environmental or 
occupational exposure to 
the product under stud y 
to a non -participant (not 
involving EDP or EDB).None. Exposure to a study 
non-participant is not 
collected on the CRF.The exposure (whether or 
not there is an associated 
AE or SAE) must be
reported.***
*EDP (with or without an associated AE or SAE): any pregnancy information is reported to 
[COMPANY_007] Safety using CT SAE Report Form and EDP Supplemental Form; if the EDP is 
associated with an SAE, then the SAE is reported to [COMPANY_007] Safety using the CT SAE Report 
Form. 
** EDB is reported to [COMPANY_007] Safety using the CT SAE Report Form which w ould also include 
details of any SAE that might be associated w ith the EDB. 
***Environmental or Occupational exposure: AEs or SAEs associated with occupational exposure 
are re ported to [COMPANY_007] Safety using the CT SAE Report Form. 
When an AE or SAE occurs, it is the responsibility  of the investigator to review all 
documentation (eg, hospi[INVESTIGATOR_1088], laboratory  reports, and diagnostic 
reports) related to the event.
The investigator will then record all relevant AE or SAE information in the CRF.

PF-[ADDRESS_1066852] 2021
PFIZER CONFIDENTIAL
Page 69It is notacceptable for the investigator to send photocopi[INVESTIGATOR_10914]’s 
medical records to [COMPANY_007] Safety  in lieu of completion of the CT SAE Report 
Form /AEor SAE CRF 
page.
There may  be instances when copi[INVESTIGATOR_19952] b y [COMPANY_007] Safety .In this case, all participant identifiers, with the 
exception of the participant number, will be redacted on the copi[INVESTIGATOR_776763] .
The investigator will attempt to establish a diagnosis of the event based on signs, 
symptoms, and/or other clinical information. Whenever possible, the diagnosis (not 
the individual signs/sy mptoms) will be documented as the AEor SAE.
Assessment of Intensity
The investigator will make an assessment of intensity for each AE and SAE reported 
during the stud y and assign it to 1 of the following categories: 
Mild: Asymptomatic or mild sy mptoms; clinical or diagnostic observations only ; 
intervention not indicated.
Moderate: Minimal, local or noninvasive intervention indicated; limiting 
age-appropriate instrumental ADL. Instrumental ADL refers to preparing meals, 
shoppi[INVESTIGATOR_3112], using the telephone, ma naging money , etc.
Severe: Severe or medically  significant but not immediately  life-threatening; 
hospi[INVESTIGATOR_3111]; disabling, limiting self 
care ADL. Self care ADL refers to bathing, dressing and undressing, feed ing self, 
using the toilet, taking medications, and not bedridden.
An event is defined as “serious” when it meets at least 1 of the predefined outcomes as 
described in the definition of an SAE, NOT when it is rated as severe.
Assessment of Causality
Theinvestigator is obligated to assess the relationship between stud y intervention 
and each occurrence of each AE or SAE. The investigator will use clinical 
judgment to determine the relationship.
A “reasonable possibility” of a relationship conveys that the re are facts, evidence, 
and/or arguments to suggest a causal relationship, rather than a relationship cannot 
be ruled out.

PF-[ADDRESS_1066853] 2021
PFIZER CONFIDENTIAL
Page 70Alternative causes, such as underl ying disease(s), concomitant therap y, and other 
risk factors, as well as the temporal relationship of the event to stud y intervention 
administration, will be considered and investigated.
The investigator will also consult the IB and/or product information, for marketed 
products, in his/her assessment.
For each AE or SAE, the investigator must document in the medical notes that 
he/she has reviewed the AE or SAE and has provided an assessment of causality .
There may  be situations in which an SAE has occurred and the investigator has 
minimal information to include in the initial report to the sponsor .However, it is 
very important that the investigator always make an assessment of causality 
for every event before the initial transmission of the SAE data to the sponsor .
The investigator may  change his/her opi[INVESTIGATOR_19954] -up 
information and send a nSAE follow -up report with the updated causality  
assessment.
The causality  assessment is one of the criteria used when determining regulatory  
reporting requirements.
If the investigator does not know whether or not the study  inter vention caused the 
event, then the event will be handled as “related to study  intervention ” for reporting 
purposes, as defined b y the sponsor . In addition, if the investigator determines that 
an SAE is associated with study  procedures, the investigator mus t record this 
causal relationship in the source documents and CRF, and report such an 
assessment in the dedicated section of the CT SAE Report Form and in accordance 
with the SAE reporting requirements.
Follow -Up of AEs and SAEs
The investigator is obligated to perform or arrange for the conduct of supplemental 
measurements and/or evaluations, as medically  indicated or as requested by  [CONTACT_103] ,to elucidate the nature and/or causalit y of the AE or SAE as full y as 
possible. This may  include additio nal laboratory  tests or investigations, 
histopathological examinations, or consultation with other healthcare providers .
If a participant dies during participation in the study or during a recognized 
follow -up period, the investigator will provide [COMPANY_007] Safet y with a cop y of any 
postmortem findings
,including histopathology .

PF-[ADDRESS_1066854] 2021
PFIZER CONFIDENTIAL
Page 71New or updated information will be recorded in the originally  submitted 
documents .
The investigator will submit any  updated SAE data to the sponsor within 24 hours 
of receipt o f the information.
10.3.4. Reporting of SAEs
SAE Reporting to [COMPANY_007] Safety via an Electronic Data Collection Tool
The primary  mechanism for reporting an SAE to [COMPANY_007] Safety will be the 
electronic data collection tool.
If the electronic s ystem is unavailable, then the site will use the paper SAE data 
collection tool ( see next section) to report the event within 24 hours.
The site will enter the SAE data into the electronic sy stem as soon as the data
become available.
After the stud y is completed at a given site , the electronic data collection tool will 
be taken off -line to prevent the entry  of new data or changes to existing data.
If a site receives a report of a new SAE from a study  participant or receives updated 
data on a previously  reported SAE after the ele ctronic data collection tool has been 
taken off -line, then the site can report this information on a paper SAE form (see 
next section) or to [COMPANY_007] Safety  by [CONTACT_756].
SAE Reporting to [COMPANY_007] Safety via CT SAE Report Form
Facsimile transmission of the CT SAE Report Form is the preferred method to 
transmit this information to [COMPANY_007] Safety .
In circumstances when the facsimile is not working , notification by  [CONTACT_20021] a cop y of the CT SAE Report Form sent by  [CONTACT_776772].
Initial notification via telephone does not replace the need for the investigator to 
complete and sign the CT SAE Report Form pages within the designated reporting 
time frames.

PF-[ADDRESS_1066855] 2021
PFIZER CONFIDENTIAL
Page 7210.4. Appendix 4: Contraceptive and Barrier Guidance
10.4.1. Male Participant Reprod uctive Inclusion Criteria
Male participants are eligible to participate if they  agree to the following requirements during 
the intervention period and for at least 28daysafter the last dose of stud y intervention, which
corresponds to the time needed to eliminate reproductive safet y risk of the study  
intervention(s):
Refrain from donating sperm.
PLUS either :
Be abstinent from heterosexual intercourse with a female of childbearing potential as 
their preferred and usual lif estyle (abstinent on a long -term and persistent basis) and 
agree to remain abstinent .
OR
Must agree to use contraception/barrier as detailed below:
Agree to use a male condom and should also be advised of the benefit for a 
female partner to use a highl y effective method of contraception as a condom may  
break or leak when having sexual intercourse with a woman of childbearing 
potential who is not currently  pregnant.
Inaddition to male condom use, a highl y effective method of contraception may be 
considered in WOCBP partners of male participants (refer to the list of highly  
effective methods below inSection 10.4.4).
10.4.2. Female Participant Reproductive Inclusion Criteria
A female participant is eligible to participate if she i s not a WOCBP (see definitions below in 
Section
10.4.3 ).
10.4.3. Woman of Childbearing Potential
A woman is considered fertile following menarche and until becoming postmenopausal 
unless permanentl y sterile (see below).
If fertility  is unclear (eg, amenorrhea in adolescents or athletes) and a menstrual cy cle cannot 
be confirmed before the first dose of study  intervention, additional evaluation should be 
considered.
Women in the following categories are notconsidered WOCB P:

PF-[ADDRESS_1066856] 2021
PFIZER CONFIDENTIAL
Page 731.Premenopausal female with 1 of the following:
Documented h ysterectomy ;
Documented bilateral salpi[INVESTIGATOR_1656] ;
Documented bilateral oophorectom y.
For individuals with permanent infertility  due to an alternate medical cause other than 
the above, (eg, mullerian agenesis, androgen insensitivity ), investigator discretion 
should be applied to determining study  entry .
Note: Documentation for any  of the above categories can come from the site 
personnel’s review of the participant’s medical records, medical examinat ion, or 
medical history  interview. The method of documentation should be recorded in the 
participant’s medical record for the stud y.
2.Postmenopausal female .
A postmenopausal state is defined as no menses for 12 months without an 
alternative medical cause. In addition :
A high FSH level in the postmenopausal range must be used to confirm a 
postmenopausal state in women under 60 years old and not using hormonal 
contraception or HRT. 
A female on HRT and whose menopausal status is in doubt will be required to 
use one of the nonestrogen hormonal highly effective contraception methods 
if they  wish to continue their HRT during the study .Otherwise, they  must 
discontinue HRT to allow confirmation of postmenopausal status before study  
enrollment.
10.4.4. Contracepti onMetho ds
Contraceptive use b y men or women should be consistent with local availability /regulations 
regarding the use of contraceptive methods for those participating in clinical trials.
Highly Effective Methods That Have Low User Dependen cy
1.Implantable progestogen -only hormone contraception associated with inhibition of 
ovulation.
2.Intrauterine device .
3.Intrauterine hormone -releasing s ystem.
4.Bilateral tubal occlusion (eg, bilateral tubal ligation).

PF-[ADDRESS_1066857] 2021
PFIZER CONFIDENTIAL
Page 745.Vasectomized partner .
A vasectomized partner is a highl y effective contraceptive method provided that 
the partner is the sole sexual partner of the WOCBP and the absence of sperm has 
been confirmed. If not, an additional highl y effective method of contraception 
should be used. The s permatogenesis cy cle is approxi mately  90days.
Highly Effective Methods That Are User Dependent
6.Sexual abstinence .
Sexual abstinence is considered a highl y effective method only  if defined as 
refraining from heterosexual intercourse during the entire period of risk associated 
with the study  intervention. The reliability  of sexual abstinence needs to be 
evaluated in relation to the duration of the stud y and the preferred and usual 
lifesty le of the participant.

PF-[ADDRESS_1066858] 2021
PFIZER CONFIDENTIAL
Page 7510.5. Appendix 5: Genetics
Use/Analysis of DNA
Genetic variation may  impact a participant’s response to study  intervention, 
susceptibility  to, and severity  and progression of disease. Therefore, where local 
regulations and IRB s/ECsallow, a blood sample will be collected for DNA anal ysis.
The scope of the genetic research may  benarrow (eg, 1or more candidate genes ) or
broad (eg,the entire genome ),as appropriate to the scientific question under 
investigation.
The samples may  be analy zed as part of a multistudy  assessment of genetic factors 
involved in the response to PF-07304814 or study  interventions of this class to 
understand treatments for the disease(s) under study  or the disease(s) themselves.
The results of genetic analy ses may  be reported in the CSR or in a separate study  
summary , or may  be used for internal decision making without being included in a 
study  report.
The sponsor will store the DNA samples in a secure storage space with adequate 
measures to protect confidentiality . 
The samples will be retained as indicated:
Retained samples will be stored indefinitely  or for an other period as per local 
requirements.
  
Participant s may  withdraw their consent for the storage and/or use of their Retained 
Research Samples at an y time by  [CONTACT_7328] a request to the investigator; in this case, 
any remaining material will be destroy ed. Data already  generated from the samples 
will be retained to protect the integrit y of existing anal yses.  
Samples for genetic research will be labeled with a code. The key  between the code 
and the participant ’s personally  identify ing information (eg,name, address) will be 
held securely  at the study site.

PF-[ADDRESS_1066859] 2021
PFIZER CONFIDENTIAL
Page 7610.6. Appendix 6: Liver Safety: Suggested Actions and Follow-U p Assessments
Potential Cases of Drug- Induced Liver Injury
Humans exposed to a drug who show no sign of liver injury  (as determined by  [CONTACT_20023]) are termed “tolerators,” while those who show transient liver injury  but adapt 
are termed “adaptors.” In some participant s, transaminase elevations are a harbinger of a 
more serious potential outcome. These participant s fail to adapt and therefore are 
"susceptible" to progressive and serious liver injury, commonl y referred to as DILI. 
Participant s who experience a transamina se elevation above 3 ×ULN should be monitored 
more frequently  to determine if they  are “adaptor s” or are “susceptible.”
In the majority  of DILI cases, elevations in AST and/or ALT precede TBili elevations 
(>2×ULN) b y several days or weeks. The increase in TBili ty pi[INVESTIGATOR_216474]/ALT 
is/are still elevated above 3 ×ULN (ie, AST/ALT and TBili values will be elevated within 
the same lab oratory sample). In rare instances, by [CONTACT_22858], 
AST/AL T values might have decreased. This occurrence is still regarded as a potential DILI. 
Therefore, abnormal elevations in either AST OR AL T in addition to TBili that meet the 
criteria outlined below are considered potential DILI (assessed per Hy ’s law criteria) cases
and should alway s b
e considered important medical events, even before all other possible 
causes of liver injury  have been excluded.
The threshold of laboratory  abnormalities for a potential DILI case depends on the 
participant ’s individual baseline values and underly ing cond itions. Participant s who present 
with the following laboratory  abnormalities should be evaluated further as potential DILI 
(Hy’s law) cases to definitively  determine the etiology  of the abnormal laboratory  values:
Participant s with AST/ALT and TBili baseli ne values within the normal range who 
subsequently  present with AST OR AL T values >3 ×ULN AND a TBili value 
>2× ULN with no evidence of hemol ysis and an alkaline phosphatase value 
<2×ULN or not available.
For participant s with baseline AST OR ALT ORTBili values above the ULN, the 
following threshold values are used in the definition mentioned above, as needed, 
depending on which values are above the ULN at baseline:
Preexisting AST or ALT baseline values above the normal range: AST or ALT 
values >2 times the baseline values AND >3 ×ULN; or >8 ×ULN (whichever is 
smaller).
Preexisting values of TBili above the normal range: TBili level increased from 
baseline value b y an amount of at least 1 × ULN orif the value reaches 
>3×ULN (whichever is smaller).

PF-[ADDRESS_1066860]/AL T and TBili separated b y more than a few weeks should be assessed 
individually  based on clinical judgment; any  case where uncertainty  remains as to whether it 
represents a potential Hy’s law case should be reviewed with the sponsor. 
The participant should return to the investigator site and be evaluated as soon as possible, 
preferabl y within [ADDRESS_1066861] and AL T and TBili for suspected Hy ’s law 
cases , additional laboratory  tests should include albumin, CK, direct and indirect bilirubin, 
GGT, PT/INR, total bile acids, and alkaline phosphatase. Consideration should also be given 
to drawing a separate tube of clotted blood and an anticoagulated tube of blood for further 
testing, as needed, for further contemporaneous analy ses at the time of the recognized initial 
abnormalities to determine etiology . A detailed history , inclu ding relevant information, such 
as review of ethanol, acetaminophen /paracetamol (either by  [CONTACT_20025] a coformulated 
product in prescription or over -the-counter medications) , recreational drug, or supplement 
(herbal) use and consumption, family  history , sexual history , travel history, history  of contact 
[CONTACT_4490] a jaundiced person, surgery , blood transfusion, history  of liver or allergic disease, and 
potential occupational exposure to chemicals, should be collected. Further testing for acute 
hepatitis A, B, C , D, and E infection
,liver imaging (eg, biliary  tract) ,and collection of serum 
sample s for acetaminophen/paracetamol drug and/or protein adduct levels may be warranted. 
All cases demonstrated on repeat testing as meeting the laboratory  criteria of AST/A LT and 
TBili elevation defined above should be considered potential DILI (Hy ’s law) cases if no 
other reason for the LFT abnormalities has yet been found. Such potential DILI (Hy’s law) 
cases are to be reported as SAEs, irrespective of availability of all the results of the 
investigations performed to determine etiology of the LFT abnormalities.
A potential DILI (Hy ’s law) case becomes a confirmed case onl y after all results of 
reasonable investigations have been received and have excluded an alternative e tiology .

PF-[ADDRESS_1066862] 2021
PFIZER CONFIDENTIAL
Page 7810.7. Appendix 7: ECG Findings of Potential Clinical Concern
ECG Findings T hat May Q ualify as AEs
Marked sinus bradycardia (rate <40 bpm) lasting minutes.
New PR interval prolongation >280 ms ec.
New prolongation of QTcF to >480 ms ec(absolute) or by≥60msecfrom baseline .
New -onset atrial flutter or fibrillation, with controlled ventricular response rate:
ie,rate<120 bpm .
New -
onset typeI second - degree (Wenckebach) AV block of >30 seconds’ duration.
Frequent PVCs, triplets , orshort intervals (<30 seconds) of consecutive ventricular 
complexes .
ECG Findings T hat May Q ualify as SAEs
QTcF prolongation >500 ms ec.
New ST- T changes suggestive of my ocardial ischemia .
New -onset l eft bundle branch block (QRS >120 msec).
New -onset right bundle b ranch block (QRS >120 ms ec).
Symptomatic bradycardia .
Asystole:
In awake, s ymptom -free participant s in sinus rhy thm, with documented periods 
of as ystole ≥3.0 seconds or an y escape rate <40 bpm, or with an escape rhy thm 
that is below the AV node. 
In awake, s ymptom -free participant s with atrial fibrillation and brad ycardia 
with [ADDRESS_1066863] 5 seconds or longer. 
Atrial f lutter or fibrillation, with rapid ventricular response rate: rapid = rate 
>120 bpm.
Sustained s upraventricular tachycardia (rate >12 0bpm) (“sustained ”= short 
duration with relevant symptoms or lasting >1 minute) .

PF-[ADDRESS_1066864] 2021
PFIZER CONFIDENTIAL
Page 79Ventricular r hythms >30 seconds’ duration, including idioventricular rhy thm ( heart 
rate <40 bpm), accelerated idioventricular rh ythm (HR > 40bpm to <100 bpm),and 
monomorphic/poly morphic ventricular tach ycardia (HR >100 bpm (such as
torsades de pointes) ).
Type IIsecond -degree (Mobitz II)AVblock.
Complete (third
-degree) heart block.
ECG Findings T hat Q ualify as SAEs
Change in pattern suggestive of new myocardial infarction .
Sustained ventricular t achy arrhy thmias (>30 seconds ’duration) .
Second- or third -degree AV block requiring pacemaker placement.
Asystolic pauses requiring pacemaker placement.
Atrial flutter or fibrillation with rapid ventricular re sponse requiring cardioversion
.
Ventricular fibrillation/ flutter .
At the discretion of the investigator, an y arrh ythmia classified as an adverse 
experience .
The enumerated list of major events of potential clinical concern are recommended as “alerts ”or 
notifications from the core ECG lab oratory to the investigator and [COMPANY_007] study team ,and not to be 
considered as all inclusive of what to be reported as AEs/SAEs.

PF-[ADDRESS_1066865] 2021
PFIZER CONFIDENTIAL
Page 8010.8. Appendix 8: Abbreviations
The following is a list of abbreviations that may  be used in the protocol.
Abbreviation Term
Abs absolute
ADL activities of daily living
ADME absorption, distribution, metabolism, excretion
AE adverse event
AESI adverse events of special interest
ALT alanine aminotransferase
API [INVESTIGATOR_776764] [ADDRESS_1066866] moment curve from time 0 extrapolated to 
infinite time
AV atrioventricular
BBS Biospecimen Banking S ystem
-hCG beta-human chorionic gonadotropin
BMI body  mass index
BP blood pressure
bpm beats per minute
BUN blood urea nitrogen
C24 observed plasma concentration at [ADDRESS_1066867] quantifiable time point 
estimated from the log -linear regression anal ysis
Cmax maximum observed concentration
CO 2 carbon dioxide (bicarbonate)
CONSORT Consolidated Standards of Reporting Trials
COVID -[ADDRESS_1066868] European Clinical Trials Database
FAS full analysis set
FSH follicle -stimulating hormone
GCP Good Clinical Practice
GGT gamma -glutamy l transferase
GLP Good Laboratory  Practice
HBsAg hepatitis B surface antigen
HCVAb hepatitis C antibody
HIV human immunodeficiency virus
HR heart rate
HRT hormone replacement therap y
IB Investigator’s Brochure
IBS irritable bowel s yndrome
ICD informed consent document
ICH International Council for Harmonisation
ID identification
IND Investigational New Drug 
INR international normalized ratio
IP manual investigational product manual
IPAL Investigational Product Accountability  Log
IRB Institutional Review Board

PF-[ADDRESS_1066869] visit
MCH mean corpuscular hemoglobin
MCHC mean corpuscular hemoglobin concentration
MCV mean corpuscular volume
MRT mean residence time
msec millisecond
MTD maximum tolerated dose
N/A not applicable
NHP nonhuman primate
NOAEL no-observed -adverse -effect level
PCR polymerase chain reaction
PCRU [COMPANY_007] clinical research unit
PD pharmacod ynamic(s)
PE physical exam
pH negative log of the h ydrogen ion concentration
PI [INVESTIGATOR_19959](s)
PR pulse rate
PT prothrombin time
PVC premature v entricular contraction/complex
QA quality  assurance
QTc corrected QT
QTcF corrected QT (Fridericia method)
qual qualitative
RNA ribonucleic acid
RT-PCR reverse transcription polymerase chain reaction
SAE serious adverse event
SAI site administration instructions
SAP Statistical Analysis Plan
SARS -CoV2 severe acute respi[INVESTIGATOR_19960] [ADDRESS_1066870] upper limit of normal
US [LOCATION_002]
Vss steady -state volume of distribution following IV infusion
WBC white blood cell
WHO World Health Organization
WOCBP woman /women of childbearing potential
WONCBP woman/women of non-childbearing potential

PF-[ADDRESS_1066871] 2021
PFIZER CONFIDENTIAL
Page 8411.REFERENCES
1. Who Situation Report 51. 11 March 2020 Available from : 
https://www.who.int/emergencies/diseases/novel- coronavirus- 2019/situation -reports . 
Accessed: 29 March 2020.
2. Johns Hopkins University of Medicine Coronavirus Resource Center. Available from: 
https://co ronavirus.jhu.edu/. Accessed: 21 March 2021.
3. Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus 
disease 2019 (COVID -19) outbreak in China: summary  of a report of 72,314 cases from 
the Chinese Center for Disease Control and Pre vention. JAMA .2020;323(13):1239 -42.
4. Richardson S, Hirsch JS, Narasimhan M, et al. Presenting characteristics, comorbidities, 
and outcomes among 5700 patients hospi[INVESTIGATOR_776747] D-19 in the [LOCATION_001] City  
area. JAMA .2020;323(20):2052-9.
5. Dochert y AB, Har rison EM, Green CA, et al. Features of 20 133 [LOCATION_006] patients in hospi[INVESTIGATOR_768779]- 19 using the ISARI C WHO Clinical Characterisation Protocol: prospective 
observational cohort study. BMJ .2020;369:m1985.
6.
Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospi[INVESTIGATOR_9645] 
2019 novel coronavirus -infected pneumonia in Wuhan, China. JAMA 
2020;323(11):1061 -9.
7. Cummings MJ, Baldwin MR, Abrams D, et al. Epi[INVESTIGATOR_623] , clinical course, and 
outcomes of criticall y ill adults with COVID- 19 in [LOCATION_001] Ci ty: a prospective cohort 
study . Lancet .2020;395([ZIP_CODE])(06):1763-70.
8. Chen T, Wu D, Chen H, et al. Clinical characteristics of 113 deceased patients with 
coronavirus disease 2019: retrospective stud y. BMJ .2020;368:m1091.
9. Mao L , Jin H, Wang M, et al. Neurol ogic manifestations of hospi[INVESTIGATOR_776765] 2019 in Wuhan, China. JAMA Neurol .2020;77(6):683-90.
10. Mehta P, McAuley  DF, Brown M, et al. COVID -19: consider cy tokine storm 
syndromes and immunosuppression. Lancet .2020;395([ZIP_CODE])(03): 1033-4.
11.
Anand K, Ziebuhr J, Wadhwani P, et al. Coronavirus main proteinase (3CLpro) 
structure: basis for design of anti -SARS drugs. Science. 2003;300(5626):1763-7.
12. Resendez JC, Rehagen D. I nfusion toxicology  and techniques. In: A comprehensive 
guide to tox icology  in nonclinical drug development. 2nd ed. Amsterdam: Elsevier; 
2017:555-83. DOI: http://dx.doi.org/10.1016/B978 -0-12 -803620-4.[ZIP_CODE]-9 .
